Tumor recognition by natural killer cells in acute myeloid leukemia and after hematopoietic stem cell transplantation by Nowbakht, Pegah
 1 
Tumor Recognition by Natural Killer Cells 
in Acute Myeloid Leukemia 
and after Hematopoietic Stem Cell 
Transplantation 
 
 
Inauguraldissertation 
 
 
 
zur 
Erlangung der Doktorwürde 
vorgelegt der 
Philosophisch-Naturwissenschaftlichen Fakultät 
der Universität Basel 
 
von 
 
Pegah Nowbakht 
aus Riehen (BS) 
 
Basel, 2005 
 
2 
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von  
 
 
Prof. Dr. sc. tech. Beat Ernst, Fakultätsvertreter 
Prof. Dr. phil. Peter Erb, Externer Korreferent 
Prof. Dr. phil. Aleksandra Wodnar-Filipowicz, Korreferentin und Dissertationsleiterin 
 
 
 
 
Basel, den 11.01.05 
 
 
Prof. Dr. sc. techn. Hans-Jakob Wirz,  
Dekan der Philosophisch-Naturwissenschaftlichen Fakultät 
TABLE OF CONTENTS 
3 
Table of Contents 
Abbreviations 6 
I. SUMMARY 8 
II. INTRODUCTION 10 
1. Natural Killer Cells 10 
1.1. NK Cell Subsets 11 
1.2. Target Recognition 12 
1.2.1 Missing Self Recognition 13 
1.2.1.1. Inhibitory Receptors 13 
1.2.2. Activating Receptors 14 
1.2.2.1 Natural Cytotoxicity Receptors (NCRs) 16 
1.2.2.2. NKG2D Receptor 19 
1.2.3. NKG2D Ligands 21 
1.2.3.1. MICA and MICB 22 
1.2.3.2. ULBP1, ULBP2 and ULBP3 23 
1.2.3.3. Murine NKG2D Ligands 24 
1.3. NK Cells in Leukaemia 25 
2. Monocytes 26 
2.1. Monocyte Function 27 
2.2. Dendritic Cell and NK Cell Interactions 28 
3. Acute Myeloid Leukaemia (AML) 29 
3.1 Characterization and Classification 29 
3.1. AML Treatment 32 
3.1.1. Induction of Remission 32 
3.1.2. Allogeneic Stem Cell Transplantation 33 
III. RESEARCH OBJECTIVES 35 
IV. MATERIALS AND METHODS 37 
1. Flowcytometry (FACS) 37 
1.1 FACS Analysis of NKG2D Ligands on PB and BM Derived  Subpopulations 37 
TABLE OF CONTENTS 
4 
1.2 FACS Analysis of NCR Dimer Binding 38 
1.3 FACS Analysis of in vitro Generated Dendritic Cells 38 
1.4 FACS Analysis of NK Cells 39 
2. Purification of Cell Populations 39 
2.1 Cell Purification by Magnetic-Activated Cell Sorting  (MACS) 40 
2.2 Cell Purification by FACSorting 41 
3. Cell Cultures 42 
3.1 Progenitor Cell Cultures 42 
3.2 Myeloid Cell Cultures 42 
3.3 Dendritic Cell Cultures 43 
3.4 NK Cell Cultures 43 
4. mRNA Expression of ULBP1, ULBP2 and ULBP3 44 
4.1 Isolation of mRNA from Purified PB Subpopulations and  RT-PCR 44 
4.2 Real-Time PCR of ULBP mRNAs 45 
5. Cytotoxicity Assays 45 
5.1 Calcein Release Assay to Measure Killing of Cell Lines 46 
5.2 Chromium Release Assays to Measure Killing of Primary  Cells 46 
6. IFN-γ Production by NK Cells 47 
6.1 IFN-γ Release Detected by ELISA 47 
6.2 IFN-γ Production by Purified NK Cell Subsets Detected by  FACS 48 
7. Primary Materials 49 
7.1 Healthy Donors 49 
7.2 AML Patients 49 
7.3 Patients after Hematopoietic Stem Cell Transplantation  (HSCT) 50 
V. RESULTS 52 
1. Analysis of Expression and Regulation of Ligands for  NKG2D and NCRs 52 
1.1 ULBP Expression on PB Derived MNCs 52 
1.1.1  ULPB Molecules Are Expressed on B cells, Monocytes, Granulocytes and Platelets 52 
1.1.2  mRNA Expression of ULBPs on B Cells and Monocytes 54 
1.2 MIC Ligands Expressed on B Cells and Monocytes 55 
1.3 NKG2D Ligands Are Absent on in vitro Derived Dendritic  Cells 56 
1.4 Validation of Soluble NCR Dimers 58 
TABLE OF CONTENTS 
5 
1.5 Expression of NCR Ligands on B Cells and Monocytes 61 
1.6 Expression of NCR and NKG2D Ligands Is Low on AML  Blasts 62 
1.7 NKG2D and NCR Ligands Are Absent on BM Progenitors 65 
1.8 Progenitors and Monocytes Are Protected from Killing by  Autologous NK Cells 66 
1.9 In Vitro Upregulation of ULBP1 and NCR Ligands 68 
1.9.1 ULBP1 and NCR Ligand Upregulation on Monocytes 68 
1.9.2 ULBP1 and NCR Ligands Are Upregulated upon Myelomonocytic  Differentiation of BM 
Progenitors 70 
1.9.3 Upregulation of Ligands for Activatory NK Cell Receptors on  AML Blasts Increases NK 
Cell Mediated Killing 71 
2. Characterization of NK Cells in AML Patients 75 
2.1 Evaluation of PB Cell Subpopulations in AML Patients 76 
2.2 Expression of MHC Class I Molecules on AML Blasts 77 
2.3 Activating Receptors Are Expressed Normally on NK Cells  from AML Patients 78 
3. Characterization of NK Cells in Patients after  HSCT 79 
3.1 NK Cell Reconstitution in Transplanted Patients 80 
3.2 Phenotypic Analysis of NK Cells after Allogeneic HSCT 81 
3.3 IFN-γ Production by NK Cells from Transplanted Patients 82 
VI. DISCUSSION 84 
1. Expression and Role of NK Activating Ligands in  Normal PB Cells 84 
2. Expression and Role of NK Activating Ligands in  AML 87 
3. Characterization of NK Cell Compartment after  HSCT 90 
VII. REFERENCES 93 
ABBREVIATIONS 
6 
Abbreviations 
 
ADCC Antibody-dependent cellular cytotoxicity 
AML Acute myeloid leukemia 
APC Allophycocyanin 
APCs Antigen presenting cells 
BM Bone marrow 
BSA Bovine serum albumin 
CD40L CD40 ligand 
CFU-GM colony-forming-units for granulocytes and monocytes 
CML Chronic myeloid leukaemia 
CMV Cytomegalovirus 
DC Dendritic cell 
EBV Epstein-Barr virus 
ELISA Enzyme-linked immunosorbent assay 
FAB French–American–British 
FACS Flowcytometry (fluorescence activated cell sorting) 
FcγRIII Fcγ receptor III 
FCS Fetal calf serum 
FITC Fluorescein isothiocyanate 
FL Flt3 ligand 
G-CSF Granulocyte colony stimulating factor 
GFs Growth factors 
GM-CSF Granulocyte macrophage colony-stimulating factor 
GPI Glysosylphosphatidylinositol 
gtαms Goat anti-mouse 
gtαrat goat anti-rat 
GvH Graft-versus-host 
GvHD Graft-versus-host-disease 
GvL  Graft-versus-leukaemia 
h/hu human 
HA Hemagglutinin 
HLA Human leukocyte antigen 
HSCT Hematopoietic stem cell transplantation 
iDC immature dendritic cell 
IFN Interferon 
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IL Interleukin 
IL-2Rαβγ heterotrimeric IL-2 receptor 
IL-2Rβγ heterodimeric IL-2 receptor 
IMDM Iscove's modified Dulbecco's medium 
ITAM Immunoreceptor tyrosine based activation motive 
ITIM Immunoreceptor tyrosine-based inhibitory motif 
KIR Killer cell immunoglobulinlike receptors 
LFA-1 Lymphocyte-function associated antigen-1 
LPS Lipopolysaccharide 
mAb Monoclonal antibody 
MACS Magnetic-acivated cell sorting 
M-CSF Macrophage colony-stimulating factor 
mDC mature dendritic cell 
MDS Myelodysplastic syndrome 
MFI Mean fluorescence intensity 
MHC Major histocompatibility complex 
MIC MHC class I-related chain 
MIP Macrophage inflammatory protein 
MNC Mononuclear cell 
mPB mobilized PB 
NCR Natural cytotoxicity receptors 
NK Natural killer 
PB Peripheral blood 
PE Phycoerythrin 
PerCP Peridin chlorophyll protein 
PHA Phytohemagglutinin 
PI3K Phosphatidylinositol 3-kinase 
Rae1 Retinoic acid early inducible 1 proteins 
RT Reverse transcription 
s soluble 
SCF Stem cell factor 
TCR T cell receptor 
TNF Tumor necrosis factor 
Tpo Thrombopoietin 
ULBP UL16 binding protein 
VLA-4 Very late after activation antigen-4 
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I. Summary 
 
Natural killer (NK) cell-mediated cytolytic activity against tumors requires the 
engagement of activating NK cell receptors by the tumor-associated ligands. Here, we 
studied the role of NKG2D and natural cytotoxicity receptors (NCRs) in the recognition 
of human leukemia.  
Hematopoietic stem cell transplantation (HSCT) is a common therapy in acute myeloid 
leukemia (AML) and newly developing NK cells are important for engraftment and 
antitumor immunity and thus for treatment outcome. Here, we studied the recovery and 
functional activity of NK cells after allogeneic HSCT. 
 
Analysis of ULBP1, ULBP2 and ULBP3, the recently identified ligands for NKG2D, and 
of the yet not defined ligands for NKp30, NKp44 and NKp46 in healthy hematopoietic 
cells demonstrated ligand expression by peripheral blood (PB) derived B cells, 
monocytes, granulocytes and platelets. We show that upregulation of cell surface ligands 
occurs during myeloid development with ligand-negative bone marrow (BM)-derived 
CD34+ progenitor cells acquiring ligand expression upon myeloid maturation in vivo and 
in vitro. ULBP1 and putative ligands for NKp30, NKp44 and NKp46 were further 
elevated by stimulation with interferon (IFN)-γ. 
In acute myeloid leukemia (AML), leukemic blasts from about 80% of patients expressed 
very low levels of NKG2D- and NCR-specific ligands. Treatment with differentiation-
promoting myeloid growth factors, flt3 ligand (FL), stem cell factor (SCF) and 
granulocyte macrophage colony-stimulating factor (GM-CSF) together with IFN-γ 
upregulated cell surface levels of ULBP1 and putative NCR ligands on AML blasts, 
conferring an increased sensitivity to NK cell-mediated lysis.  
We conclude that the ligand-negative/low phenotype in AML is a consequence of cell 
maturation arrest upon malignant transformation and that defective expression of ligands 
for the activating NKG2D and NCR receptors may be an underlying cause for 
compromised leukemia recognition by NK cells. In addition, NK cells were significantly 
decreased in AML patients, but they expressed NKG2D and the NCRs at normal high 
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levels, providing a further argument for a dominant role of activating ligands and not 
their respective receptors in immune escape in AML. 
 
Analysis of NK cells after allogeneic HSCT revealed a rapid reconstitution of NK cells, 
which reached normal levels as soon as 1 month after HSCT. However, there was a 
skewing of NK cell subpopulations, with a prevalence of IFN-γ producing 
CD56brightCD16dim/- NK cells and a corresponding reduction in the highly cytotoxic 
CD56dimCD16bright subset. Expression of the triggering receptor NKp46 in NK cells from 
transplanted patients was high. Our results indicate that fast recovering NK cells may 
have important implications in the prevention of leukemic relapses after allogeneic 
HSCT. 
 
Altogether these data indicate that low expression of ligands for activating NK cell 
receptors on leukemic blasts results in poor immunogenicity of tumor cells. Moreover, in 
vivo upregulation of those ligands on target cells by appropriate compounds might 
improve recognition of blasts by NK cells, including the early developing allogeneic NK 
cells after HSCT, and thus reduce leukemic relapses. 
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II. Introduction 
 
1. Natural Killer Cells 
 
NK cells are effector cells of the peripheral immune system. They comprise about 5-10% 
of PB lymphocytes and can be distinguished from other cell types by the expression of 
surface markers CD56 and CD16, and the absence of CD3. NK cells are also found in 
peripheral tissues including the liver, peritoneal cavity and placenta1,2. 
NK cells derive from hematopoietic stem cells. Since thymectomized or splenectomized 
mice and humans3-6 have normal numbers of functional NK cells, neither spleen nor 
thymus appears to be essential for the generation of NK cells. Present consensus states 
that BM is the main site for NK cell generation. Interleukin (IL)-15 was found to be the 
crucial factor for the development of human and murine NK cells7-10. FL or SCF increase 
the frequency of NK cell precursors through upregulation of expression of the IL-15 
receptor complex7,11. FL or IL-15 deficient mice have markedly reduced numbers of NK 
cells9,12. 
NK cells are part of the innate immune system and as such, they are able to kill cancer 
and virus-infected cells without need for prior antigen stimulation1. Activation of NK 
cells results in the release of cytotoxic mediators as well as in the production of several 
cytokines and chemokines, including IFN-γ, tumor necrosis factor (TNF)-α, TNF-β, GM-
CSF, macrophage inflammatory protein (MIP)-1α, MIP-1β and I-30913,14. NK cells are 
highly responsive to many cytokines, including IL-2, IL-12, IL-15 and IFNs which 
rapidly increase their proliferative, secretory, cytolytic and anti-tumor functions15. 
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1.1. NK Cell Subsets 
 
Based on their cell-surface density of CD56, human NK cells can be divided into two 
subsets, CD56bright and CD56dim cells (see Figure II-1). Each subset displays distinct 
phenotypic and functional properties16. The majority (≈90%) of human NK cells are 
CD56dim and express high levels of Fcγ receptor III (FcγRIII, CD16), whereas ≈10% of 
NK cells are CD56brightCD16dim or CD56brightCD16negative. 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure II-1. NK Cell Subsets 
 
 
The CD56 antigen is an isoform of the human neural-cell adhesion molecule with 
unknown function for human NK cells17, although early studies suggested that this 
molecule might mediate interactions between NK cells and target cells18,19. Thus, there is 
no known direct functional significance of high – or low - level of CD56 expression. So 
far, no murine homologue of CD56 has been found. Consequently, it is not known, 
whether mice have NK cell subsets analogous to CD56bright and CD56dim cells. 
CD16 is the low-affinity FcγRIII on the surface of NK cells. It binds to the Fc portion of 
antibodies. CD16 signals through associated subunits containing an immunoreceptor 
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tyrosine based activation motive (ITAM). Binding of CD16 to antibody-coated, 
opsonized, targets directly results in antibody-dependent cellular cytotoxicity (ADCC)20. 
Early studies of resting CD56dim NK cells revealed that these cells are naturally more 
cytotoxic than CD56bright NK cells21, although after activation with IL-2 or IL-12 in vitro 
or following low dose therapy with IL-2, CD56bright and CD56dim cells have similar levels 
of cytotoxicity22-24. Freshly isolated CD56bright human NK cells are the primary source of 
NK cell derived immunoregulatory cytokines, including IFN-γ, TNF-β, IL-10, IL-13 and 
GM-CSF, whereas the CD56dim NK cell subset produces consistently negligible amounts 
of these cytokines following stimulation with recombinant monokines in vitro25. 
All NK cells express a functional heterodimeric IL-2 receptor (IL-2Rβγ) with 
intermediate affinity for IL-2. In 1990, it was shown that the CD56bright NK cells 
constitutively express the high-affinity heterotrimeric IL-2R (IL-2Rαβγ)22,23. This subset 
has a high proliferative response to low doses of IL-2 alone and can be expanded in vitro 
and in vivo in response to picomolar concentrations of IL-226,27. By contrast, resting 
CD56dim NK cells express IL-2Rβγ only and show almost no proliferation in response to 
high doses of IL-2 in vitro22,27. 
 
 
1.2. Target Recognition 
 
A role for NK cells in rejection of tumors and virus infected cells in vivo has been 
proposed shortly after their discovery as a unique lymphocyte subset28,29. From studies 
performed to date two general mechanisms have been implicated for NK cells in target 
cell recognition: missing self recognition, and recognition of ligands for activating NK 
cell receptors. Unlike T and B lymphocytes, NK cells do not rearrange genes encoding 
receptors for antigen recognition, but they have the ability to recognize target cells 
through inhibitory and stimulatory receptors expressed on the cell surface of NK cells. 
The balance between activating and inhibiting signalling determines the triggering status 
of the NK cells. 
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1.2.1 Missing Self Recognition 
 
Initially, Karre et al proposed that NK cells discriminate target cells based on the levels 
of target cell self-MHC (major histocompatibility complex) class I expression. By 
comparing the activity of NK cells against wild type and class I-low tumor cell lines it 
was shown that NK cells preferentially attack cells with reduced or abolished MHC class 
I expression30. Resistance to NK cell-mediated cytotoxicity of class I-low tumors could 
be restored by reintroduction of class I molecules31,32. In further support of this model, 
three families of inhibitory, MHC class I-recognizing, receptors expressed by NK cells 
were subsequently discovered. The first inhibitory receptor identified was Ly49 in mice33-
35. Subsequently, killer cell immunoglobulinlike receptors (KIRs; also collectively termed 
CD158) were discovered in humans36-39 and CD94/NKG2A in both mice and humans40-
43. 
 
 
1.2.1.1. Inhibitory Receptors 
 
A key aspect of the immune system is the ability to respond to target molecules alien to 
the organism while sparing the organism itself. Equally critical is the capacity to limit 
and ultimately terminate a response, inactivating or eliminating the relevant pathways 
when they are no longer required. Loss of inhibitory signalling is often associated with 
autoreactivity and uncontrolled inflammatory responses44. 
In human NK cells two families of inhibitory receptors, KIR and CD94/NKG2A 
recognizing MHC class I ligands prevent from autoreactivity. The cytoplasmic domains 
of all inhibitory NK cell receptors contain an immunoreceptor tyrosine-based inhibitory 
motif (ITIM) with the consensus sequence I/VxYxxL/V45,46. These domains recruit 
intracellular tyrosine phosphatases SHP-1 or SHP-2 that mediate the inhibition of 
cytotoxicity and cytokine release45,47-49. 
KIRs are encoded by about 12 polymorphic genes and recognize polymorphic epitopes 
on human leukocyte antigen classes HLA-A, HLA-B and HLA-C. KIRs are expressed on 
subsets of NK cells and also memory T cells. 
INTRODUCTION 
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The CD94/NKG2A receptor, conserved in rodents and primates, is a disulfide-bonded 
heterodimer. It is typically expressed in about 50% of the NK cells and a subset of 
memory CD8+ T cells. CD94 lacks cytoplasmic signalling domain while NKG2A 
contains two ITIMs49,50. This heterodimeric receptor recognizes tetramers of the human 
non-classical MHC molecule HLA-E and the homologous mouse Qa1b molecule. While 
KIR, and also murine Ly49, directly binds to intact MHC class I molecules, 
CD94/NKG2A binds to a peptide derived from the signal sequence of classical MHC 
class I molecules that is presented in the groove of HLA-E and Qa1b51,52. In the absence 
of these peptides, HLA-E and Qa1b are retained in the cytoplasm of the host cells and 
degraded. Expression of several class I alleles is needed to get maximal protection 
through CD94/NKG2A53, indicating that the signal sequence-derived peptide is in limited 
supply. NK cells, relying entirely on CD94/NKG2A for inhibition, are well suited to 
detect a reduction in the overall synthesis of MHC class I antigen. 
The various MHC specific inhibitory receptor genes are expressed by overlapping subsets 
of NK cells such that an individual cell expresses a few types of inhibitory receptors. This 
leads to a complex combinatorial repertoire of NK specificities for MHC class I 
molecules. Expression of the inhibitory receptor repertoire among NK clones is 
stochastic. The only rule appears to be that every NK cell has at least one inhibitory 
receptor specific for a self-MHC class I molecule in order to avoid autoreactivity. 
 
 
1.2.2. Activating Receptors 
 
Beside inhibitory receptors NK cells express a wide panel of stimulatory receptors (listed 
in Table II.1). The biological roles of many of these receptors are not well understood, 
primarily because many of the ligands have not been identified and genetic loss-of-
function studies have not yet been carried out in most cases. The main triggering 
receptors identified to date are the NCRs and the NKG2D receptor (see Figure II-2). 
Their activation results in direct killing of target cells and can even override negative 
signals generated by engagement of inhibitory MHC class I receptors13,54-56. In addition, 
CD257, CD1658, CD6959 and DNAM-160 have been shown to trigger NK cell-mediated 
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killing in redirected cytotoxicity assays. Another activating NK cell receptor is NKp80, 
which belongs to the type II C-lectin-like receptor family. NKp80 acts as a coreceptor 
and functions synergistically with NCRs. The NKp80-mediated recognition of target cells 
has been documented in killing of phytohemagglutinin (PHA) transformed blasts, while 
lysis of various tumor cell lines could not be inhibited by masking NKp80 with mAbs61.  
 
 
 
 
 
 
 
 
 
 
 
 Figure II-2. Activating NK Cell Receptors 
 
 
Some members of the KIR and NKG2 receptor family also have activation properties. 
NKG2C and NKG2E are stimulatory members of the CD94/NKG2 family40,62,63. They 
recognize (similarly to their inhibitory counterparts) the Qa1 molecule in mice62 and the 
HLA-E molecule in humans64. KIR2DS and KIR3DS are stimulatory members of the 
KIR family65-67. There is evidence that the activating receptors bind the self-MHC class I 
with lower affinity as compared to the inhibitory receptors68. Thus autoimmunity could 
be prevented by a balance towards negative NK cell regulation. Similar to the inhibitory 
receptors, the MHC class I-specific stimulatory receptors are expressed in a variegated 
and predominantly stochastic fashion by subsets of NK cells69.  
Commonly, activating receptors lack the ITIM motif in their cytoplasmic domains. 
Instead, they have charged residues in their transmembrane domains that are necessary 
for association with adaptor signalling proteins, which have short extracellular domains 
NKp30 NKp46 NKp44 NKG2D
ITAM YxxM
DAP12 DAP10 
CD3ζ 
FcεRIγ 
CD3ζ CD3ζ
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and are not likely to participate in ligand binding. Instead, the intracellular domains of the 
adaptor proteins have docking sites for downstream stimulatory signalling molecules. 
Most adaptors (FcεRγI, CD3ζ and DAP12) contain ITAMs in their cytoplasmic domains, 
which allow them to associate with ZAP70 and/or syk-family kinases70,71. DAP10, which 
so far only associates with NKG2D72,73, has a YxxM motif in its transmembrane domain, 
which allows recruitment of phosphatidylinositol 3-kinase (PI3K) (see Figures II-
3,4)72,74.  
 
 
Table II-1. Stimulatory Receptors on Human NK Cells 
 Ligands Adaptors Expression pattern 
Stimulatory receptors recognizing MHC class I molecules 
NKG2C, NKG2E HLA-E DAP12 variegated 
KIR2DS HLA-C DAP12 variegated 
KIR3DS HLA molecule DAP12 variegated 
    
Stimulatory receptors recognizing non-MHC class I molecules 
NKG2D MICA, MICB,  
ULBP1, 2, 3, 
RAET1E, RAET1G 
DAP10 All NK cells, all CD8+ αβ T cells,  
ca. 50% of NKT cells, γδ T-cell 
subset 
NKp46 viral hemagglutinin CD3ζ, FcεRγI All NK cells 
NKp44 viral hemagglutinin DAP12 All NK cells after IL-2 stimulation 
NKp30 unknown CD3ζ, FcεRγI All NK cells 
CD16 IgGs CD3ζ, FcεRγI Most NK cells 
 
 
1.2.2.1 Natural Cytotoxicity Receptors (NCRs) 
 
So far three different NCRs (see Figure II-2) have been cloned, namely NKp46, NKp44 
and NKp3054,75,76. Molecular cloning of NCRs confirmed that they are structurally 
distinct from each other76. The NCRs belong to the immunoglobulin superfamily77. While 
NKp46 and NKp30 are expressed uniquely on both non-activated and activated NK cells, 
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NKp44 is present on IL-2 activated NK cells only and on a minor subset of T cell 
receptor (TCR)-γδ+ T cells75.  
NCR surface density varies among individuals. Thus, NK cells from some donors 
homogeneously express the NCRs at high density (NCRbright), whereas in other 
individuals two subsets of NK cells carrying either high or low (NCRdim) receptor 
densities were detected76,78. Importantly, NCRdim clones display a low cytolytic activity 
compared to that of NCRbright clones isolated from the same or a different individual78,79. 
NKp46, the first NCR identified, is a 46kDa glycoprotein with a protein backbone of 
approximately 33kDa. Its transmembrane domain contains a positively charged arginine, 
which interacts with an aspartic acid residue in the transmembrane domain of the adaptor 
molecule CD3ζ 54,80,81. Triggering of NKp46 results in Ca2+ mobilization, cytolytic 
activity and cytokine production54. It was later suggested that the NKp46 was the major 
lysis receptor in NK cells, since anti-NKp46 monoclonal antibody (mAb) blocked the 
lysis of a large panel of tumor cells78. Involvement of NKp46 was also demonstrated 
through the lysis of autologous Epstein-Barr virus (EBV)-transformed cell lines, which 
are protected from NK cell mediated killing by the expression of self HLA class I 
molecules. Masking of HLA class I induces efficient killing of autologous EBV-
transformed cell lines by NK cells. Additional mAb-mediated masking of NKp46 results 
in significant (50-60%) inhibition of lysis thus implying that NKp46-specific ligands are 
also expressed in normal cells78. This result also shows that the triggering function of 
NKp46 is negatively regulated by the interaction between inhibitory receptors and HLA 
class I molecules. 
NKp46 homologue has been cloned in mouse81 and rat82 displaying around 60% identity 
with the human NKp46. The human receptor was also found to induce killing of YAC-1 
cells, murine lymphoma cell line, indicating that its ligand may be conserved in humans 
and mice78,80. 
NKp44 is a 44kDa glycoprotein present on IL-2 stimulated NK cells, suggesting that it 
may contribute to the increased efficiency of activated NK cells to elicit tumor cell 
lysis1,75. NKp44 contains a charged lysine in its transmembrane region that participates in 
association with the ITAM bearing DAP12 adaptor molecule75. mAb mediated masking 
of NKp44 resulted in partial inhibition of cytolytic activity against certain tumor target 
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cells83. This inhibition was greatly increased by additional masking of NKp46. Therefore 
NKp44 appears to function as a NCR selectively expressed by activated NK cells, which 
may cooperate with NKp46. Surface density of NKp44 correlates in most instances to 
that of NKp46 (NKp46/p44bright and NKp46/p44dim clones)83. 
NKp30 is a 30kDa glycoprotein that associates with the adaptor molecules CD3ζ and 
FcεRIγ through a positively charged amino acid in the transmembrane region76. Its 
surface expression correlates to that of NKp46. NKp30 was shown to co-operate with 
NKp46 and NKp44 in the induction of cytotoxicity against a variety of target cells. It was 
shown to represent the major receptor responsible for killing of those tumor target cells 
which were largely NKp46/p44 insensitive76. 
Importantly, no cellular ligands for NCRs have been described, yet. NKp46 and NKp44 
but not NKp30 can recognize viral hemagglutinins (HA). The binding of the receptors to 
HA involves sialic acid residues on the NCRs. The activating signalling resulting from 
the interaction of HA with NKp46 and NKp44 could overcome inhibitory signalling 
mediated by MHC class I molecules expressed on the target cells and resulted in killing 
of influenza virus infected cells56,84. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 Figure II-3. NCRs, Signalling Cascade 
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1.2.2.2. NKG2D Receptor 
 
NKG2D was first identified in 1991 by the discovery of the respective cDNA expressed 
by human NK cells40. Further characterization of this receptor was hampered by technical 
difficulties in expressing NKG2D on the cell surface by transfection. So its role was 
ignored up to 1999 when it was found that NKG2D needs association to the adaptor 
molecule DAP10 for its surface expression (see Figure II-4) and when NKG2D was 
identified as an activating receptor for an MHC class I like molecule, MIC A55,72. 
NKG2D is a type II C-lectin-like protein encoded by a gene located next to the NKG2A, 
C, E genes within the NK gene complex on human chromosome 12p12-p13 and mouse 
chromosome 6. Due to this chromosomal localization NKG2D was originally classified 
as a member of the NKG2 family. However, it has only 20% sequence homology with 
the highly conserved NKG2 isoforms and does not associate with CD94 but forms a 
homodimeric structure72. 
NKG2D is constitutively expressed on all human and mouse NK cells73. It can be 
upregulated on human cells by IL-15, IL-12 and IFN-α85. NKG2D is also detectable on 
all human γδ T cells and CD8+ αβ T cells55, and is upregulated on CD8+ T cells by IL-
1586. In mouse, NKG2D surface expression has also been detected on macrophages 
stimulated with LPS, IFN-γ or IFN-α/β73,87. 
NKG2D couples through the positively charged arginine in its transmembrane domain 
with the opposite charged aspartic acid residue in the transmembrane region of DAP10. 
Upon cross-linking of NKG2D the cytoplasmic YxxM motif of DAP10 is tyrosine 
phosphorylated and can recruit the p85 subunit of PI3K, resulting in the activation of Akt. 
DAP10 has also been shown to bind the adaptor protein Grb272,74. Signalling via PI3K 
plays a pivotal role in the pathway that triggers cytotoxicity of NK cells. Pharmacological 
inhibition of PI3K blocked killing by preventing mobilization of perforin and granzyme 
B to the cell-cell interface between the NK cell line NK92 and Raji target cells88. 
Rejection of NKG2D ligand-expressing murine RMA or RMA-S lymphoma cell lines 
required functional perforin but not IFN-γ, indicating that degranulation of pore-forming 
cytotoxic granules, rather than release of IFN-γ from NK cells and CD8+ T cells, is the 
main effector mechanism for tumor rejection89. 
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Engagement of NKG2D also leads to calcium mobilization as well as the activation of 
JAK2, STAT5 and the ERK MAP kinases (see Figure II-4). Consequently, binding of 
cognate NKG2D ligands results in enhanced survival, proliferation and cytotoxicity, as 
well as cytokine and chemokine production (IFN-γ, GM-CSF, TNF-α and TNF-β, MIP-
1α and β, and I-309)85,90. NKG2D engagement complements NCRs in mediating NK-
dependent lysis of tumor cells91. Similarly, cooperation between NKG2D and activating 
KIRs has been shown for both cytotoxicity and IFN-γ secretion92. It is thus possible that 
on human NK cells, NKG2D may serve both as a primary receptor whose engagement 
triggers cytotoxicity, and also as a co-stimulation molecule, which cooperates with other 
activating receptors (e.g. activating KIR or NCR) for cytokine secretion. Indeed on 
cytomegalovirus (CMV)-specific CD28-CD8+ αβ T cells and γδ T cells, NKG2D acts as 
a co-stimulatory molecule for TCR-dependent signals93-95. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Figure II-4. NKG2D, Signalling Cascade 
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1.2.3. NKG2D Ligands 
 
NKG2D recognizes several families of cellular ligands, all of which are distantly related 
to MHC class I molecules. NKG2D ligands are upregulated on tumor cells, virally 
infected cells and ‘stressed’ cells (see Figure II-5). Blockade of the NKG2D receptor-
ligand interaction results in reduced NK mediated killing of NKG2D ligand-positive 
tumor cell lines, suggesting that the expression of NKG2D ligands on target cells potently 
induces NK cell cytotoxicity87,91,96. Depending on the levels of NKG2D ligands, the 
stimulatory signal can override inhibitory signals provided by the same target 
cell13,55,96,97. However, the stimulatory signal transmitted by NKG2D is not entirely 
refractory to inhibitory signals91. 
Many human tumors of epithelial origin and most mouse tumor cell lines of diverse 
origin express ligands for NKG2D98,99. The fact that so many NKG2D ligands exist in 
both human and mouse, and that NKG2D is expressed not only on NK cells but also on T 
cells and macrophages, suggests that the NKG2D receptor likely plays an important role 
in innate and adaptive immune responses to pathogens and tumors. 
 
 
 
 
 
 
 
 
 
 Figure II-5. Human and Murine NKG2D Ligands 
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endoplasmic reticulum and cis-Golgi apparatus, specifically binds MICB, ULBP1 and 
ULBP2, and causes their retention within infected cells. In cells expressing the NKG2D 
ligands, cotransfection with UL16 encoding cDNA markedly reduces cell surface levels 
of MICB, ULBP1 and ULBP2, and decreases susceptibility to NKG2D mediated 
cytotoxicity100-102. 
 
 
1.2.3.1. MICA and MICB 
 
The first identified human NKG2D ligands were the MHC class I-related chain A and B 
(MICA/B), which were shown to bind to NKG2D expressed on NK cells, CD8+ T cells 
and γδ+ T cells. MICA/B expressing tumor cells were specifically killed by NK cells, 
demonstrating that NKG2D was a functional receptor for MICs55. The human MICA and 
MICB genes map in the MHC class I region, close to the HLA-B locus103. They code for 
heavily glycosylated proteins with low homology (18-30%) to HLA-A, -B and –C, and 
consist of an α1, α2 and α3 region (see Figure II-5). Considerable polymorphism exists 
for the MICA and MICB genes, and 54 alleles of MICA and 16 alleles of MICB have 
been defined103 with substitutions throughout the α1, α2 and α3 regions. In contrast to 
MHC class I molecules, MICs do not require β2-microglobulin or peptide binding for 
protein folding and stable surface expression104,105. 
Transcripts of MICs are found in low abundance in many cells, but surface expression of 
MIC protein is rare in adult tissue. MICs become upregulated in many epithelial tumor 
cells98, in cells infected with hCMV94, in bacterially infected cells106 and in stressed 
cells104. A low level of MICA/B expression is maintained on the epithelial cells lining the 
gastrointestinal surfaces, which may be due to interactions of these cells with various 
environmental stress factors104. MIC genes are under the control of promotor elements 
similar to those of the HSP70 genes. Indeed, heat shocking of epithelial lines at 42°C for 
2 hours was shown to increase expression of MIC transcripts and proteins104. Since cell 
culture at 42°C is not of physiological relevance, the mechanisms leading to MIC 
upregulation in transformed cells remain unknown. Although NKG2D receptors are 
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conserved among mouse, rat and human, no homologues of MIC ligands have been 
identified in mice. 
Groh et al. found that epithelial tumor cells are able to shed MICs. Binding of soluble 
MICs to NKG2D results in endocytosis and degradation of the receptor. This 
downregulation of NKG2D expression on NK cells, CD8+ T cells and γδ T cells leads to 
decreased cytolytic activity against target cells107. Thus, MIC shedding serves as a 
mechanism of epithelial tumors to escape recognition by NK and T cells. 
 
 
1.2.3.2. ULBP1, ULBP2 and ULBP3 
 
The UL16 binding proteins (ULBPs) were initially identified based on the ability of some 
members (ULBP1 and ULBP2) to interact with UL16, a protein encoded by hCMV. In 
parallel, it was shown that soluble ULBPs bind to NKG2D/DAP10 heterocomplexes and 
that anti-NKG2D mAb completely blocked binding of ULBPs to primary NK cells13. 
ULBP1, ULBP2 and ULBP3 are 55-60% identical among each other. They are distantly 
related to members of the extended MHC class I family, with whom they share 23-26% 
amino acid sequence identity. ULBPs possess α1 and α2 domains but differ from 
traditional MHC class I molecules in that they lack an α3 domain and do not associate 
with β2-microglobulin (see Figure II-5). ULBPs are glysosylphosphatidylinositol (GPI)-
linked rather than transmembrane proteins. Furthermore, unlike most members of the 
extended MHC class I family, including the MICs, which map to chromosome 6p21, 
genes for ULBPs are localized outside the MHC region on chromosome 6q2513. ULBPs 
lack many of the conserved amino acids that are known to be important for peptide 
binding by classical MHC class I molecules108 and are therefore unlikely to present 
peptide antigens. 
ULBP messages are expressed in a wide range of tissues, including heart, lung, testis, 
thymus, PB and BM. But the protein expression doesn’t always correlate with the 
presence of mRNA. In addition, comparison of ULBP message levels in several matched 
normal and tumor tissue samples showed no consistent differences13,109. How ULBP 
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protein expression is controlled under physiological and pathological conditions requires 
further studies.  
Expression of ULBPs on NK cell resistant, MHC class I positive lymphoblastoid B cell 
line Daudi, transfected with β2-microglobulin, rendered the Daudi cells sensitive to NK 
cell lysis. The killing of Daudi cells was mediated through the binding of ULBPs to the 
NKG2D receptor on NK cells, since Fab fragments of both anti-ULBP and anti-NKG2D 
mAbs completely blocked killing13. Together, these findings show that engagement of 
NKG2D with ULBPs generates an activating signal that can override a negative signal 
transduced by inhibitory receptors for MHC class I and trigger NK cytotoxicity. This is in 
line with the fact that NK cells were not only shown to kill cells with downregulated 
MHC class I, such as some tumor and virus-infected cells, but also cells with unaltered 
expression of MHC class I110-113. 
Stimulation of NK cells with soluble ULBPs leads to production of several cytokines and 
chemokines, including GM-CSF, TNF-α, TNF-β and IFN-γ, playing an important role in 
antiviral immunity13,14. 
Recently, other members of the ULBP family have been cloned, RAET1E (ULBP4) and 
RAET1G. In contrast to ULBP1,-2 and -3, RAET1E and RAET1G are transmembrane 
proteins with cytoplasmatic tails. RAET1G but not RAET1E binds to hCMV protein 
UL16. Surface expression of RAET1G and RAET1E results in NKG2D dependent killing 
of target cells by human NK cells114,115. 
 
 
1.2.3.3. Murine NKG2D Ligands 
 
Two families of ligands, Rae1 and H60, for the mouse NKG2D receptor have been 
cloned73,116. The retinoic acid early inducible 1 proteins (Rae1) are encoded by a family 
of five very closely related genes (Raet1a-e)117. H60 was initially identified as a 
dominant minor histocompatibility antigen in the response of C57BL/6 mice against 
BALB.B cells118. H60 and Rae1 proteins are distantly related to class I molecules. Like 
ULBPs, the RAE-1 proteins are GPI-linked proteins, whereas H60 is a transmembrane 
protein, similar to RAET1E and RAET1G. The basic structure of RAE-1 and H60 
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proteins, consisting of only α1 and α2 domains, is similar to the one of the ULBPs (see 
Figure II-5). However, murine NKG2D ligands share very low sequence identity with the 
ULBPs and MICs, indicating that they represent functional rather than true evolutionary 
homologues. 
Most interestingly, the Rae1 proteins are, like MICs, not expressed by most normal cells, 
but are upregulated by many tumor cells of diverse origin73,99,119. H60 is expressed by 
some tumor cells from BALB/c mice but is also expressed at low levels by activated 
lymphoblasts and at high levels by BALB/c thymocytes73. 
 
 
1.3. NK Cells in Leukaemia 
 
Deficient HLA class I expression has been described in leukaemic cells120-122 making 
them candidate targets for NK cells. However, this phenomenon is not ubiquitously 
observed in leukaemia. 
In chronic myeloid leukaemia (CML) NK cell number and NK cell function has been 
shown to decrease progressively during the spontaneous course of the disease123. Both 
NK cell number and function recover upon IFN-α treatment124. Moreover, activated 
autologous NK cells were shown to suppress growth of primitive CML progenitors in 
long-term culture125.  
In AML analysis of NK cell function demonstrated impaired NK cell activity in 16 out of 
18 patients. The impaired cytotoxic function correlated with a low NCR surface density 
(NCRdim). The remaining two patients were characterized by NK cells having an 
NCRbright phenotype, but were unable to kill autologous blasts in vitro. Importantly, the 
leukaemic blasts from these two patients were also resistant to lysis mediated by normal 
NCRbright allogeneic NK cells, indicating that expression of NCR ligands in those blasts 
was low or absent79. NK cell activity in AML was further shown to correlate positively 
with the relapse-free survival of patients in complete remission126.  
In leukaemia patients treated with haplotype mismatched stem cell transplantation, donor 
derived NK cells have been reported to exert an antileukaemic effect. This graft-versus-
leukaemia (GvL) effect, which so far had only been attributed to the function of CD8+ T 
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cells, was due to KIR epitope-mismatch in the graft-versus-host (GvH) direction. Missing 
expression of KIR ligands on mismatched cells of the recipient triggered NK cell 
alloreactivity against the leukemic blasts. Despite the high number of alloreactive NK 
cells, there was no evidence of graft-versus-host-disease (GvHD). And interestingly, the 
alloreactive response persisted only for a period of four months, after which time it was 
no longer detectable127. The clinical outcome of transplantation was more favourable in 
the patients with alloreactive NK cells: in this group, the probability of five-year ‘event-
free’ survival was 60%, compared with 5% in the patients who did not receive 
alloreactive NK cells128. 
Altogether these data suggest that NK cells play an important role in the control and 
clearance of leukaemic cells. 
 
 
2. Monocytes 
 
Monocytes are generated in the BM. They derive from a progenitor cell, the CFU-GM, 
which also gives rise to granulocytic cells. The maturation process of monocytic lineage 
in vivo starts at a monoblast stage, passes through the promonocyte stage and 
subsequently ends up as monocytes151. IL-3, GM-CSF and macrophage colony-
stimulating factor (M-CSF) stimulate in vivo generation of monocytes152. In vitro, 
hematopoietic progenitor cells cultured with GM-CSF induce CFU-GM to differentiate 
towards granulocytes, while addition of FL and SCF shifts differentiation from 
granulocytic to monocytic lineage153,154. Newly formed monocytes leave the BM within 
24 hours and migrate to the PB. Circulating monocytes adhere to endothelial cells of the 
capillary vessels and are able to migrate into various tissues155. This adherence and 
migration involves surface proteins, lymphocyte-function associated antigen-1 (LFA-1), 
CD11 and very late after activation antigen-4 (VLA-4), belonging to the intergrin 
superfamily of adhesion molecules156. These integrins interact with selectins on 
endothelial cells. Monocytes which migrated into tissues differentiate into macrophages. 
According to their localization macrophages have distinct names (e.g microglia in central 
nervous system and Kupffer cells in the liver). Some mononuclear phagocytes may 
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differentiate into dendritic cells. Since proliferation of macrophages is very limited, 
renewal of the macrophage population depends on the influx of monocytes and their local 
proliferation and differentiation157,158.  
 
 
2.1. Monocyte Function 
 
Monocytes are members of the mononuclear phagocyte system. During inflammation 
monocytopoiesis increases159,160 resulting in elevated monocyte numbers. Furthermore, 
inflammatory mediators, IL-1, IL-4, IFN-γ and TNF-α upregulate expression of selectins 
on endothelial cells promoting migration of monocytes into tissues. The same cytokines 
modulate expression of the adhesion molecule integrin on monocytes161. At the site of 
inflammation monocytes are involved in the phagocytosis of opsonized microorganisms 
or immune complexes via surface Fcγ receptors (CD64, CD32) and complement 
receptors (CD11b, CD11c). The microorganisms are synergistically killed by reactive 
oxygen and nitrogen metabolites and through several hydrolytic enzymes (acid 
phosphatase, esterase, lysozyme and galactosidase)162-164. Importantly, monocytes 
stimulate T cells by antigen presentation and thus, are involved in the recognition and 
activation phases of adaptive immune responses165,166. 
Monocytes secrete a large number of bioactive products which play an important role in 
inflammatory, proliferative and immune responses, including growth factors (GM-CSF, 
G-CSF, M-CSF, IL-1) and antiproliferating factors (IFNs, TNF)166. 
Lipopolysaccharide (LPS) or endotoxin is a predominant integral structural component of 
the outer membrane of Gram-negative bacteria and one of the most potent microbial 
initiators of inflammation. LPS binds to the CD14 glycoprotein that is expressed on the 
surface of monocytes. The binding of LPS induces production of TNF-α, IL-1, -6, -8 and 
-10167-169. Other than LPS, one of the most efficient stimuli for cytokine production in 
vitro is the direct cell-cell contact of monocytes with activated lymphocytes170,171. Mature 
T cells express CD40 ligand (CD40L) and it has been demonstrated that interaction of 
CD40L with CD40, a member of the TNF-receptor family, on monocytes induces the 
production of several cytokines172-174. Furthermore, incubation of monocytes with 
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CD40L-transfected cells results in tumoricidal activity against a human melanoma cell 
line. CD40 expression on monocytes can be upregulated by IFN-γ, IL-3 and GM-CSF 174. 
Functional interactions between monocytes and NK cells have been described. 
Monocytes have a proliferative effect in vitro on cultured NK cells. This effect is in part 
mediated by soluble factors but is enhanced through direct cell-cell contact175. In addition 
release of IL-12, TNF-α, IL-15 or IL-1β by activated monocytes induces production of 
IFN-γ by cocultured NK cells176,177. Short-term cultures of NK cells with monocytes 
increased cytotoxic potential of NK cells, whereas long-term cultures resulted in decrease 
of NK cytotoxicity178,179, suggesting time dependent functional interactions between the 
two cell populations. 
 
 
2.2. Dendritic Cell and NK Cell Interactions 
 
Dendritic cells (DCs) are components of the innate immune system. They circulate 
through the blood and non-lymphoid peripheral tissues, where they can become resident 
cells180. Immature DCs (iDCs) recognize pathogens through cell surface receptors, 
including Toll-like receptors181. After uptake of antigen DCs mature and migrate to 
lymph nodes. Mature DCs (mDCs) are efficient antigen presenting cells (APCs) which 
mediate T cell priming180. 
A predominant role of DCs in NK cell activation has been described in mice and humans. 
Both immature and bacterially activated human monocyte-derived DCs have been shown 
to induce cytokine secretion and cytotoxicity by NK cells182,183. Moreover, infected DCs 
are much stronger inducers of NK cell activation and proliferation than uninfected 
DCs184. Conversely, in vitro crosstalk between NK cells and DCs can either promote 
cytokine release by DCs and their further maturation or results in the killing of DCs by 
autologous NK cells. At low NK to DC ratios (1 to 5) the interaction dramatically 
amplifies DC responses, whereas at high ratios (5 to 1) DCs are lysed by NK cells185,186. 
In mice mature DCs are a potential source of both IL-15 and IL-12 representing one 
possible mechanism how DCs can promote NK cell survival, differentiation and 
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activation187,188. However, in vitro studies have shown that certain types of interaction 
between NK cells and DCs requires direct cell-to-cell contact183,185. 
Interestingly, it was described that after HSCT alloreactive NK cells kill host-type DCs. 
This prevents antigen presentation of host antigens to graft T cells and thus allows to 
avoid the initiation of GvH reactions. Thus, alloreactive NK cells do not mediate GvH 
disease but rather prevent it by killing of host DCs128.  
 
 
3. Acute Myeloid Leukaemia (AML) 
 
AML is characterized by an increase in the number of myeloid cells in the BM and an 
arrest in their maturation, frequently resulting in hematopoietic insufficiency 
(granulocytopenia, thrombocytopenia, or anemia), with or without leukocytosis. The 
presence of more than 30% leukaemic blasts in a BM aspirate is required for a definitive 
diagnosis of acute leukaemia. Symptoms that are typical include fatigue, hemorrhage or 
infections and fever due to decrease in red cells, platelets or white cells, respectively.  
 
 
3.1 Characterization and Classification 
 
AML is a heterogeneous disease caused by a variety of pathogenic mechanisms. At a 
morphologic level, this heterogeneity is manifested by variability in the degree of 
commitment and differentiation of the myeloid cell lineage (see Figure II-6). This 
variability has been used to define specific morphologic subgroups. The most commonly 
used method of classification is that developed by the French–American–British (FAB) 
group (see Table II-2), which divides AML into nine distinct subtypes that differ with 
respect to the particular myeloid lineage involved and the degree of leukemic-cell 
differentiation. This distinction is based on the morphologic appearance of the blasts and 
their reactivity with histochemical stains. In addition, immunologic methods have been 
incorporated into the diagnostic criteria for some FAB subgroups, but genetic alterations 
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are not always included in the FAB classification. Currently, cytogenetic or direct 
molecular genetic methods have become an essential part of the routine diagnostic 
workup of patients with AML to identify subgroups with distinct clinical features and 
therapeutic responses. This combination of morphologic, immunologic, and genetically 
based diagnostic approaches not only makes it possible to modify the therapy according 
to the sensitivity of biologically defined subtypes, but also provides unique markers to 
monitor a patient’s response to therapy129. 
AML often results from alterations in transcriptional cascades (e.g. transcription factor 
AML1-CBFβ) that are normally involved in regulating cell fate. Other mechanisms, that 
are less frequent, involve alterations of growth factor-signalling pathways including 
structural mutations of the receptor for granulocyte colony stimulating factor (G-CSF)130. 
Cellular transformation is a multistep process and the abnormalities discussed above are 
insufficient by themselves to lead to leukaemia. Only about 50% of all AML cases 
involve chromosomal rearrangements, whereas in the remaining cases the underlying 
molecular genetic abnormalities remain to be identified. 
 
 Table II-2. AML Classification 
FAB Subtype Common Name 
M0 Acute myeloblastic leukemia with minimal differentiation 
M1 Acute myeloblastic leukemia without maturation 
M2 Acute myeloblastic leukemia with maturation 
M3 Acute promyelocytic leukemia 
M4 Acute myelomonocytic leukemia 
M5 Acute monocytic leukemia 
M6 Erythroleukemia 
M7 Acute megakaryocytic leukemia 
 
 
 
 
INTRODUCTION 
31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure II-6. AML, Differentiation Arrest 
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Treatment with topoisomerase II inhibitors, such as epipodophyllotoxins, can also result 
in therapy-induced AML134. In contrast to alkylating agent-induced secondary AML, it 
develops after a relatively short latency period of two to three years. 
 
 
3.1. AML Treatment 
 
The primary objective in treating patients with AML is to induce remission and thereafter 
prevent relapse. Remission is conventionally defined morphologically by the presence of 
less than five percent blasts in BM together with the recovery of peripheral-blood counts. 
More than 75% of patients with AML are older than 60 years. In this age group there is 
an uneven distribution of unfavourable prognostic factors (e.g., cytogenetic 
abnormalities, features of drug resistance, or a history of MDS)135,136. In addition, older 
patients poorly tolerate an intensive chemotherapy and often have intercurrent medical 
conditions that are exacerbated by cancer chemotherapy or its sequelae. Withholding 
induction chemotherapy generally results in low survival rates and a poor quality of 
life137. There is some evidence that the use of low-dose maintenance chemotherapy for 
several months after the induction of remission reduces the probability of relapse135. 
AML treatment is conventionally divided into induction and postinduction of remission.  
 
 
3.1.1. Induction of Remission 
 
Induction chemotherapy is administered to all newly diagnosed AML patients except 
those with myelodysplasia or secondary AML. With the use of daunorubicin and 
cytarabine or their analogues, complete remission can be routinely induced in 70 to 80% 
of patients who are 60 years of age or younger and in approximately 50% of older 
patients. Up to 25% of patients die of severe bacterial and fungal infections during and 
after induction therapy. Administration of growth factors, such as G-CSF and GM-CSF, 
stimulates the production and activation of granulocytes and monocytes and promotes 
their mobilization. This results in a reduced duration of neutropenia and translates into 
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fewer days of antibiotic138 or antifungal therapy139. None of the studies found that this 
approach reduced the number of documented infections. Although AML blasts generally 
express functional G-CSF and GM-CSF receptors on their surface140, the fear that 
treatment with G-CSF or GM-CSF could provoke the growth of leukaemic cells in 
patients has not been confirmed. 
 
 
3.1.2. Allogeneic Stem Cell Transplantation 
 
Once remission is induced, further intensive treatment of patients with AML is essential 
to prevent relapse. Three options are available for younger patients: allogeneic HSCT 
from an HLA matched related or unrelated donor, autologous HSCT and chemotherapy 
only without following HSCT. 
HSCT was conceived as a treatment to replace the entire hematopoietic system of the 
patient141,142. The first successful human HSCTs were carried out about 30 years ago. 
Since then it has become a routine treatment of choice for malignant and non-malignant 
disorders of hematopoiesis as well as for solid tumors142,143. BM is no longer the only 
source of stem cells. The use of mobilized PB (mPB), into which hematopietic stem cells 
migrated after administration of cytokines, predominates now144,145, and cord blood is 
used increasingly. 
Allogeneic HSCT from an HLA-matched sibling can cure 50 to 60% of recipients146,147. 
The risk of relapse among patients in first complete remission who receive an HLA-
matched transplant from a sibling is generally less than 20%. The reduced relapse rate is 
the result not only of the use of myeloablative chemotherapy prior to HSCT, but also of 
the allogeneic effect mediated by the graft against residual leukemia in the host (GvL). 
However, this favorable effect is partially offset by the toxicity of GvHD, which is 
caused by alloreactive cytotoxic CD8+ effector T cells of the donor attacking the tissues 
of the recipient, in particular skin, intestines and liver. The Matching of donors and 
recipients for MHC class I and II molecules is important to prevent GvHD, and is 
necessary for the recipient to recover a functional adaptive immune system. After 
transplantation, the recipient becomes a stable chimera, in which hematopoietic cells are 
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of donor HLA type, but all other cells are of recipient HLA type. The preferred donor for 
any patient undergoing HSCT is and HLA-identical sibling. Upon depletion of T cells to 
reduce GvHD the incidence of both graft rejection and disease relapse were increased, 
indicating that alloreactive T cells also play a favourable role in graft acceptance and 
anti-tumor responses141,148-150. 
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III. Research Objectives 
 
NK cells are important effectors of innate immunity because of their ability to lyse tumor 
cells and virus-infected cells without need for prior antigen stimulation1. The activity of 
NK cells is regulated by a balanced system of inhibiting and activating signals, which 
enable the NK cells to distinguish between healthy cells and abnormal target cells. Those 
signals are transferred through inhibitory receptors, KIR and CD94/NKG2A30, and the 
activating NK cell receptors, NKG2D and NCRs54,55. MIC and ULBP molecules have 
been identified as human ligands for NKG2D. They are expressed on epithelial tumor 
cells and several tumor cell lines, making them susceptible for NK mediated lysis13,55. 
Endogenous ligands for the NCRs, NKp30, NKp44 and NKp46, have not yet been 
discovered, although NK-dependent lysis of many tested tumor cell lines and primary 
tumor cells is NCR dependent76,80,83.  
 
AML is a heterogeneous hematopoietic disease resulting from malignant transformation 
and developmental arrest of myeloid progenitor cells at an immature differentiation stage. 
HSCT is an important therapeutic option in AML135,142. Early after HSCT, immune 
function is determined by both mature immunocompetent cells transferred with the 
allogeneic graft and by immune populations that arise from transplanted stem cells. 
Donor derived NK cells after haplotype mismatched HSCT were recently shown to exert 
an important antileukemic effect due to KIR epitope-mismatch in graft-versus-host 
direction127. Furthermore, NK cell activity in AML was shown to correlate positively 
with relapse free survival of patients in complete remission126. 
 
These previous studies show the important role of NK cells in the recognition and 
eradication of tumor cells including leukemic blasts. However, rapid disease progression 
in AML and the high incidence of relapses following treatment with chemotherapy or 
allogeneic HSCT suggest that leukemic blasts can escape recognition by NK cells. Lack 
of NK cell recognition can be due to decreased surface levels of activating NK cell 
receptors and impaired NK cell function. Another reason for the poor immunogenicity of 
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leukemic blasts could be the absence of triggering ligands on malignant cells, reflecting 
in vivo selection and possible tumor escape from NK mediated lysis. This thesis 
characterizes the properties of NK cells at the onset of AML and following HSCT with 
the goal to understand their role in leukaemia surveillance by the immune system.  
 
To address the question of poor immunogenicity of leukemic blasts, the first goal of this 
project was to analyze NK cells from AML patients for the expression of the activating 
receptors, NKG2D and NCRs, whereas leukemic blasts were examined for the expression 
of the specific ligands for these receptors. Since cellular NCR ligands are still unknown, 
complexes of recombinant NCRs were used as binding reagents recognizing the putative 
respective ligands. 
 
It may be hypothesized that high levels of triggering ligands on malignant cells might 
improve their recognition by NK cells, however, the regulation of those ligands remains 
poorly understood. Thus, the next goal of this project was to investigate conditions 
allowing to upregulate the surface expression of NKG2D and NCR ligands. The 
susceptibility of primary AML blasts to NK cell cytotoxicity was monitored in order to 
establish the optimal condition for tumor cell recognition by NK cells. 
 
After HSCT, developing NK cells are likely to function as potent effectors capable to 
eradicate residual leukemic blast. Nevertheless, relapses remain a serious post-transplant 
complication189,190. To examine whether NK cells arising from donor stem cells function 
normally, the third goal of this thesis focussed on the phenotypic and functional 
characterization of NK cells in AML patients undergoing HSCT. 
 
Findings of these studies may improve the understanding of the interactions between NK 
cells and the leukemic blasts as well as the mechanisms of tumor escape from NK cell 
recognition. In addition, new strategies of increasing susceptibility of tumor cells to NK 
cell mediated cytotoxicity may evolve. 
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IV. Materials and Methods 
 
1. Flowcytometry (FACS) 
 
Fluorescence marked cells were measured using FACS Calibur and analysis was 
performed with CellQuest software (both from Becton Dickinson, San Jose, CA). 
 
 
1.1 FACS Analysis of NKG2D Ligands on PB and BM Derived 
 Subpopulations 
 
To analyse lymphocytes, monocytes and granulocytes staining was performed in 100µL 
aliquots of heparinized PB followed by lysis of erythrocytes with FACS Lysing Solution 
(Becton Dickinson). Cells were stained at room temperature for 15 minutes with 
fluorescein isothiocyanate (FITC)-, phycoerythrin (PE)-, or allophycocyanin (APC)- 
conjugated mAb against human CD3, CD19, CD33, CD56 or isotype control antibodies 
(all from BD PharMingen, San Jose, CA). To analyse erythrocytes PB was diluted 1:1000 
with PBS and 100µL aliquots were stained at 4°C for 20 minutes with PE-conjugated 
mAb against human glycophorin-A (BD PharMingen) without lysing. To analyse 
platelets PB was spinned serially for 10 minutes at 700 rpm and 2000 rpm. 100 µL 
aliquots were stained with FITC-conjugated mAb against human CD61 (BD 
PharMingen) without lysing. 
Staining with unlabelled mAb anti-ULBP1 (M295; 10µg/mL), -ULBP2 (M311; 
20µg/mL) and -ULBP3 (M550; 10µg/mL; each a generous gift from D. Cosman, 
Immunex, WA) was detected with FITC-conjugated goat anti-mouse (gtαms) antibody 
(diluted 1:300; Jackson ImmunoResearch, West Grove, PA). Normal mouse serum 
(Jackson ImmunoResearch) was used 1:10 to saturate free binding sites of secondary 
antibodies before cells were subsequently incubated with directly labelled lineage 
specific antibodies. For MIC analysis hybridoma supernatant containing rat mAb specific 
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for MICA/B proteins (1:5; kind gift from M. Colonna, Basel Institute for Immunology, 
Switzerland) was used. Binding of anti-MICA/B mAb was revealed by secondary FITC-
labelled goat anti-rat (gtαrat) IgG (diluted 1:100; Jackson ImmunoResearch). NKG2D 
ligand expression was quantified as the mean fluorescence intensity (MFI) ratio of values 
obtained with specific mAbs divided by values given by secondary gtαms IgG and 
secondary gtαrat IgG alone. 
For leukemic patients peridin chlorophyll protein (PerCP)- conjugated anti-CD45 mAb 
(BD PharMingen) was added to distinguish blasts from residual mononuclear cells 
(MNC). To analyze ULBP expression on BM MNCs PE-conjugated anti-CD33, PerCP-
conjugated anti-CD14 and APC-conjugated anti-CD34 mAb (all BD PharMingen) were 
used.  
 
 
1.2 FACS Analysis of NCR Dimer Binding 
 
To measure putative NCR ligands, dimeric complexes of sNKp30 (10µg/mL), sNKp44 
(5µg/mL) and sNKp46 (5µg/mL) were used as staining reagents (kindly provided by G. 
De Libero, University Hospital Basel, Switzerland) and the binding was revealed using 
FITC-conjugated gtαms IgG (Jackson ImmunoResearch). Putative NCR ligand 
expression was quantified as the MFI ratio of values obtained with specific mAbs divided 
by values given by secondary gtαms IgG alone (for PB and BM derived cells) or control 
anti-BirA1.4 mouse IgG plus FITC-labelled gtαms (for tumor cell lines). Directly 
labelled lineage specific mAbs were added after blocking free binding sites of the 
secondary antibody by normal mouse serum (Jackson ImmunoResearch), as above 
 
 
1.3 FACS Analysis of in vitro Generated Dendritic Cells 
 
To detect DCs generated in vitro cells were stained with PE-labelled anti-CD1a, PerCP-
conjugated anti-CD14 and APC-labelled anti-HLA-DR mAb or isotype control 
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antibodies (Becton Dickinson). Maturity of DCs was tested using unlabelled mAb against 
human CD80, CD83 or CD86 and secondary FITC-conjugated gtαms IgG (Jackson 
ImmunoResearch). Directly labelled DC-specific mAbs were added after blocking free 
binding sites of the secondary antibody by normal mouse serum (Jackson 
ImmunoResearch), as above. NKG2D ligand expression was measured using unlabelled 
anti-ULBP1 (M295) and –ULBP3 (M550) mAbs and anti-MICA/B rat antibody 
(hybridoma supernatant; M. Colonna, Basel Institute for Immunology), as above. 
 
 
1.4 FACS Analysis of NK Cells 
 
For the analysis of NK cells heparinized PB was stained with APC-labelled anti-CD56 
mAb, PE-conjugated anti-HLA-DR, anti-CD16 or anti-CD161 mAb, FITC-labelled anti-
CD69 mAb and PerCP-conjugated anti-CD3 mAb or isotype control mAbs (all from 
Becton Dickinson).  
Staining with unlabelled anti-NKG2D mAb (at 10 µg/mL, M585; kindly provided by D. 
Cosman, Immunex) and anti-NKp46 mAb (diluted 1:5, 9E2; kind gift from M. Colonna, 
Basel Institute for Immunology) was detected with FITC-conjugated gtαms IgG (Jackson 
ImmunoResearch). Receptor expression was quantified as the MFI ratio of values 
obtained with specific mAbs divided by values given by secondary gtαms IgG alone. 
Directly labelled lineage specific mAbs were added after blocking free binding sites of 
the secondary antibody by normal mouse serum (Jackson ImmunoResearch), as above. 
 
 
2. Purification of Cell Populations 
 
To isolate specific populations from BM and PB samples, MNCs were separated by 
Histopaque (Sigma, St. Louis, MO) density-gradient centrifugation and the subsequent 
erythrocyte lysis (lysis buffer from Kantonsspital Basel, Switzerland). The cells were 
cryopreserved in liquid nitrogen until use. Frozen samples were thawed and incubated per 
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1 x 107 cells per mL overnight at 4°C in Iscove's modified Dulbecco's medium (IMDM) 
containing 10% fetal calf serum (FCS; both from Invitrogen, Carlsbad, CA) and DNase 
(500 U/mL; Sigma). For isolation process cells were resuspended in MACS buffer (PBS, 
containing 0.5% bovine serum albumin and 2mM EDTA) after washing. 
 
 
2.1 Cell Purification by Magnetic-Activated Cell Sorting 
 (MACS) 
 
To purify CD34+ progenitor cells up to 1 x 108 viable MNCs from BM or mobilized PB 
were incubated per 300 µL MACS buffer for 30 minutes with 100 µL magnetic labelled 
anti-CD34 mAb and 100 µL FcR blocking reagent (both from CD34 Progenitor Cell 
Isolation Kit, Miltenyi, Bergish Gladbach, Germany) at 4°C. After washing up to 108 
MNCs were resuspended per 1 mL MACS buffer and separated through magnetic 
columns (Miltenyi). 
To purify CD14+ monocytes PB derived viable MNCs were incubated per 107 cells in 80 
µL MACS buffer with 20 µL magnetic labelled anti-CD14 mAb (Miltenyi) for 15 
minutes at 4°C. After washing cells were resuspended per 108 MNCs in 500 µL MACS 
buffer and separated through magnetic columns (Miltenyi). 
CD56+CD3- NK cells were purified using MACS NK cell isolation kit II (Miltenyi). Per 
107 PB derived viable MNCs were incubated in 40 µL MACS buffer with 10 µL of a 
biotin labelled lineage specific antibody cocktail (against CD3, CD4, CD14, CD15, 
CD19, CD36, CD123 and glycophorin A; Miltenyi) for 10 minutes at 4°C. Next, 30 µL 
MACS buffer and 20 µL magnetic labelled anti-biotin mAb were added per 107 MNCs 
and incubated for 15 minutes at 4°C. After washing up to 108 MNCs were resuspended in 
1 mL MACS buffer and separated through magnetic columns (Miltenyi). Purified NK 
cells were collected in the flow through. 
When labelled cells corresponded up to 107 cells, MNCs were separated using a magnetic 
MS column (Miltenyi). When labelled cells corresponded up to 10 cells, MNCs were 
separated using an magnetic LS column (Miltenyi). MS and LS columns were first rinsed 
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with 500 µL and 3 mL MACS buffer, respectively, before adding MNCs through a 
MACS pre-separation filter (Miltenyi) on the column. Columns were washed 3 times 
with MACS buffer. For negative NK cell purification cells were collected in the flow 
through. For the monocyte and progenitor cell purification cells were eluted from the 
column using MACS buffer. 
Cell purity was analyzed by FACS, as described above and purified cells were put into 
cultures, as described below. 
 
 
2.2 Cell Purification by FACSorting 
 
To separate CD16bright and CD16dim/- NK cell subsets MNCs from PB of healthy donors 
and patients after HSCT NK cells were first purified by MACS, as described above. 
Subsequently, NK cells were incubated per 108 cells in 150 µL MACS buffer with FITC-
labelled anti-CD56, PE-labelled anti-CD16 and APC-labelled anti-CD3 mAb (10 µL 
each; BD PharMingen) for 20 minutes in ice and darkness. After washing cells were 
filtered (Polystyrene Tube with Cell Strainer Cap, Falcon, Becton Dickinson) and NK 
cell subsets were separated using a FACS. Isolated NK cells were restimulated prior to 
test them for INF-γ production, as described below. 
To purify CD3+ T cells, CD19+ B cells and CD14+ monocytes PB derived MNCs were 
incubated per 108 cells in 150 µL MACS buffer with FITC-labelled anti-CD3 or PE-
labelled anti-CD3 and/or FITC-labelled anti-CD14 and/or PE-labelled anti-CD19 mAb 
(10 µL each; BD PharMingen) for 20 minutes in ice and darkness. After washing cells 
were filtered (Polystyrene Tube with Cell Strainer Cap, Falcon, Becton Dickinson) and 
separated by FACSVantage SE (Becton Dickinson). Sorted cells were used for RNA 
isolation, as described below. 
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3. Cell Cultures 
 
Cells were cultured in IMDM supplemented with 2 mM L-glutamine, 100 U/ml 
penicillin, 100 µg/ml streptomycin (all from Invitrogen). 
 
 
3.1 Progenitor Cell Cultures 
 
To maintain CD34+ progenitors in vitro 8 x 105 cells were cultured in 24-well plates in 1 
mL medium containing 10% FCS (from Invitrogen), 0.5% bovine serum albumin (BSA; 
Dade-Behring, Düdingen Schweiz), transferrin (Calbiochem, La Jolla, CA), flt3 ligand 
(FL, 50 ng/mL) and thrombopoietin (Tpo, 50 ng/mL; both kindly provided by Amgen 
Inc, Thousand Oaks, CA). Killing of CD34+ progenitors using autologous NK cells was 
assessed after 3 days of in vitro culture. 
 
 
3.2 Myeloid Cell Cultures 
 
To induce myeloid differentiation 0.5 to 1 x 106 CD34+ cells were cultured in 6-well 
plates in 3 ml medium containing 10% FCS (Invitrogen), 0.5% BSA (Dade-Behring) and 
transferrin (Calbiochem) in the presence of FL at 100 ng/ml, SCF at 100 ng/ml and GM-
CSF at 20 ng/ml (all kind gifts of Amgen Inc). After 1 week generated myeloid cells 
were analyzed by FACS using mAbs against CD34 and CD33, as described above. 
To maintain CD14+ in culture, 3 x 106 cells were kept in 3 ml IMDM with FL, SCF and 
GM-CSF, as above. 
CD14+ monocytes from healthy donors and MNCs from AML patients containing > 80% 
blasts were cultured in the same condition used for myeloid differentiation. 
To induce NKG2D and NCR ligand upregulation monocytes and primary AML blasts 
were further incubated with interferon-γ (100 U/ml; PeproTech, London, UK), IL-1b (20 
U/ml; kind gift of Sandoz, Basel, Switzerland), TNF-α (50 ng/mL; kindly provided by M. 
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Fuchs, Sandoz), IFN-α (100 U/mL; Sigma) and LPS (10 ng/ml; from S. abortus equi 
NG420, kind gift of R. Landmann, Kantonsspital Basel, Switzerland) for 3 to 4 days, as 
indicated. Ligand upregulation was monitored by FACS, as described above. 
 
 
3.3 Dendritic Cell Cultures 
 
To generate DCs 1 x 106 in vitro derived myeloid cells were incubated with 10% FCS 
(Invitrogen), GM-CSF (20ng/mL; kind gift from Amgen) and IL-4 (20ng/mL; kindly 
provided by M Zurrini, Novartis, Basel, Switzerland) for 3 days. Maturation was induced 
using CD40 ligand (500ng/mL; kindly provided by S. Lyman, Immunex). Development 
and maturation of DCs and NKG2D ligand expression was analyzed by FACS as 
described above. 
 
 
3.4 NK Cell Cultures 
 
2 x 106 purified NK cells were cultured in 3 mL medium supplemented with 5% human 
AB+ serum (Blutspendezentrum, Basel, Switzerland), IL-2 (100 U/mL kind gift E. 
Andersen, Novartis), nonessential aminoacids (1:100), 1 mM sodium pyruvate, 2 mM L-
glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin and 100 µg/mL kanamycin (all 
from GIBCO Life Technologies, Grand Island, NY). After 2-4 days expression of 
activating ligands was analyzed by FACS and cytotoxic assays were performed, as 
described. 
For restimulation, 3 x 105 CD56+CD3- NK cells were seeded onto 2 x 106 irradiated (30 
Gy) allogeneic MNCs in 24-well plates containing 2 ml medium, as above, supplemented 
with PHA (1 µg/mL; Murex Biotech, Dartford, UK). When NK cell subsets were 
restimulated 6 x 104 and up to 2 x 104 NK cells were seeded onto 1 x 106 and 4 x 105 
irradiated feeder cells, respectively. 
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After 1 week proliferating NK cells were transferred into 6-well plates. Between day 12 
and 28 expression of activating ligands was analyzed by FACS, as described above, and 
restimulated NK cells were used in killing assays and IFN-γ release assays as described 
below. 
 
 
4. mRNA Expression of ULBP1, ULBP2 and ULBP3 
 
Expression of ULBP mRNA was analyzed in PB-derived CD19+ B cells, CD3+ T cells 
and CD14+ monocytes isolated by FACS sorting (>98% purity), as described above. 
 
 
4.1 Isolation of mRNA from Purified PB Subpopulations and 
 RT-PCR 
 
1 x 106 to 5 x 106 cells were used for the extraction of total cellular RNA. Cells were 
washed in PBS and centrifuged at maximal speed (12’0000rpm) for 1-2 minutes. The cell 
pellet was resuspended in 1 mL of Trizol (GIBCO Life Technologies), vortexed 
vigorously and incubated for 15 minutes at room temperature. 200 µL of chloroform was 
added, mixture was vortexed vigorously and incubated for 10 minutes at room 
temperature. To separate the lipohpilic and the aqueous phase the mixture was 
centrifuged at maximal speed. The upper hydrophilic phase was carefully transferred into 
a new tube and 500 µL (1:1 ratio) of isopropanol (Merck, Darmstadt, Germany) was 
added. After short vortexing tubes were incubated for 10 minutes at room temperature. 
The mRNA was pelleted by centrifugation at maximal speed for 15 minutes. The 
supernatant was discarded and mRNA pellet was washed in 1 ml of 70% ethanol (Fluka 
Chemie, Buchs, Switzerland) and centrifuged at maximal speed for 15 minutes. The 
ethanol was completely removed and the pellet was left to dry for several minutes. RNA 
was dissolved in 50 µL DEPC (Sigma) solution and stored at -70°C for further use in 
reverse transcription (RT)-PCR. 
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RT-PCR was performed in a total volume of 20 µL. 8 µL solution containing 1-2 µg 
RNA was mixed with 2 µL buffer (containing MgCl2; PerkinElmer, Bostin, MA), 0.75 
µL RNase inhibitor (40 U/µL; Promega, Madison, WI), 1 µL of random hexamers (50 
µM GIBCO Life Technologies), 0.25 µL SuperScriptTM II (200 U/µL; GIBCO Life 
Technologies) and 4 x 2 µL of dNTPs (10mM each; Promega). The RT reaction was 
incubated at 21°C for 12 minutes, followed by 45 minutes at 42°C and stopped at 95°C 
for 5 minutes. Resulting cDNA was stored at -20°C for further real-time PCR. 
 
 
4.2 Real-Time PCR of ULBP mRNAs 
 
For real-time PCR cDNA was amplified in duplicates using TaqMan MGB primer sets 
for ULBP1 (Hs00360941_m1), ULBP2 (Hs00607609_mH) and ULBP3 
(Hs00225909_m1) and control primers for hypoxanthine phosphoribosyl transferase 
(HPRT) (Hs00355752_m1; all from Applied Biosystems, Foster City, CA). 
Amplification (40 cycles; 95°C 15 seconds, 60°C 1 minute) was monitored using the Taq 
Man MGB probe labelled with 6-FAM dye and nonfluorescent quencher on the ABI 
Prism 7000 Sequence Detection System. 
 
 
5. Cytotoxicity Assays 
 
To analyze the killing of cell lines and primary cells, a calcein-acetyoxymethyl (calcein-
AM)-based assay or a standard chromium release assay was used, respectively. During 
the loading process NK cells were prepared in 96-well round bottom plates (Becton 
Dickinson). Serial 1:2 dilutions were done starting from an effector to target ratio of 10 in 
100 µL. Labelled target cells and blocking reagents were added to NK cells resulting in 
an endvolume of 200 µL. Target and effector cells were incubated for 4 hours at 37°C. 
Maximum Calcein or 51Cr release was determined with target cells lysed in 1% Triton-X 
(Sigma). Percentage of cytotoxicity was calculated as follows: 100 x (experimental 
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release - spontaneous release) / (maximum release - spontaneous release). Experiments 
were performed in triplicates. 
In blocking experiments anti-MHC class I mAb (10 µg/mL; W6/32, ATCC, Manassas, 
VA), control anti-MHC class II mAb (10 µg/mL; L243, hybridoma supernatant), anti-
NKG2D mAb (20 µg/mL (M585, provided by D. Cosman, Immunex) and a mixture of 
sNKp30, sNKp44 and sNKp46 (at 5, 20 and 50 µg/mL) were used as indicated. 
 
 
5.1 Calcein Release Assay to Measure Killing of Cell Lines 
 
2 x 106 THP-1, HL60 or K562 cells were labelled for 30 minutes at 37°C in the dark 
using 10 µM calcein-AM (from Calbiochem) in 1 ml serumfree M199 medium 
(purchased from Invitrogen) containing 100 U/mL penicillin and 100 µg/mL 
streptomycin (GIBCO Life Technologies). After washing cells were incubated for 
another 30 minutes at 37°C and washed again to decrease the background signal and 
target cells were added to NK cells in M199 medium containing 5% FCS. Spontaneous 
and maximal calcein-AM release was determined in six wells each. 50 µL of supernatants 
were transferred into a flat bottom 96-well plate (Becton Dickinson) and assessed for 
calcein-AM release using a Spertramax Gemini spectrofluorimeter (Molecular Devices, 
Sunnyvale, CA; excitation 485 nm, emission 530 nm). 
 
 
5.2 Chromium Release Assays to Measure Killing of Primary 
 Cells 
 
2 x 106 monocytes, CD34+ progenitors or primary blasts were labelled with 250 µCi 
Na251CrO4 (Amersham, Little Chalfont, UK) for 2 hours at 37°C. Cells were washed 
twice, incubated for 30 minutes at 37°C and washed again to decrease the background 
signal. Labelled target cells wer added to NK cells in IMDM containing 5% FCS and IL-
2 (100 U/mL; kindly provided by E. Andersen, Novartis). Spontaneous and maximal 
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chromium release was determined in three wells each. 30 µL of supernatants were 
transferred to Luma scintillation-plates (PerkinElmer), dried over night and assessed for 
chromium release using a TopCount NXT gamma-counter (Packard PerkinElmer). 
 
 
6. IFN-γ Production by NK Cells 
 
6.1 IFN-γ Release Detected by ELISA 
 
IFN-γ release by healthy NK cells after cocultures with target cells in 5% FCS 
(Invitrogen) and IL-2 (100 U/mL; kindly provided by E. Andersen, Novartis) or IL-12 
(10 U/mL; Roche, Nutley, NJ) was measured using enzyme-linked immunosorbent assay 
(ELISA). 1 x 105 THP-1 cells were put into 96-well round bottom plates (Becton 
Dickinson) and serial 1:2 dilutions were done starting from an effector to target ratio of 2 
in 50 µL. 5 x 104 restimulated NK cells from healthy donors and blocking reagents were 
added to THP-1 cells resulting in an endvolume of 100 µL. As background control NK 
cells and THP-1 cells were cultured separately. As a positive control 5 x 104 NK cells 
were cultured in the presence of IL-12 (10 U/mL; Roche) and IL-18 (100 ng/mL; 
PeproTech). After 18 hours of incubation cultures were substituted with 100 µL cytokine 
containing medium without any blocking reagents. 42 hours after coculturing plates were 
centrifuged for 2 minutes at 1400 rpm and 140 µL of supernatants were assessed for IFN-
γ release. 
Flat bottom 96-well MaxisorpTM plates (NUNC, Roskilde, Denmark) were coated at 4°C 
overnight with mouse anti-huIFN-γ  (43-11, kindly provided by Ch. Heusser, Novartis) at 
a concentration of 5 µg/mL in a volume of 50 µL per well. Plates were washed and 
blocked with RIA buffer containing 5 % BSA (Roche Diagnostics, Mannheim, Germany) 
and 0.2% Tween (Merck) for 1 hour. After washing 70 µL of culture supernatants or 
IFN-γ standard were added. Serial 1:2 dilutions of the IFN-γ  standard (recombinant hu 
IFN-γ ; from BD PharMingen)  were made starting with a final concentration of 30 
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ng/mL in BSA containing buffer. After incubating 90 minutes plates were washed and 50 
µL biotinylated mouse anti-hu IFN-γ  mAb (diluted 1:2000; 45-15, kindly provided by 
Ch. Heusser, Novartis) was added. Plates were incubated for 90 minutes, washed and 50 
µL streptavidine-alkaline phosphatase (diluted 1:2000; Sigma) was added per well. After 
incubation of 1 hour plates were washed and 150 µL substrate, p-nitrophenyl phosphate 
(Sigma) diluted 1:100 in buffer containing 0.1g/L MgCl2, was added to each well and 
incubated for 30 minutes. The enzymatic reaction was stopped by the addition of 50 µL 
NaOH solution (1M; Merck). Absorbance was analyzed at 405nm using an 
SpectraMAX190 ELISA reader (Molecular Devices). 
In blocking experiments, anti-NKG2D mAb (M585; provided by D. Cosman, Immunex), 
sNKp30, sNKp44, sNKp46 or anti-BirA1.4 mAb were added, as indicated. 
 
 
6.2 IFN-γ Production by Purified NK Cell Subsets Detected by 
 FACS 
 
PB derived CD16dim/- or CD16bright NK cell subsets were proliferated in vitro and 
assessed for IFN-γ  production by MACS IFN-γ  secretion assay (Miltenyi Biotec). 2 x 
105 NK cells were incubated in 96-well plates (Becton Dickinson) in 200 µL IMDM 
containing 5% human AB+ serum, IL-12 (10 U/mL; Roche) and IL-18 (100 ng/mL; 
PeproTech). After 18 hours at 37°C cells were washed in ice-cold MACS-buffer (see 
above). Cells were incubated for 5 minutes in ice with an IFN-γ catch reagent (1:10; 
Miltenyi) in 90 µL IMDM containing 10% FCS. Subsequently, cells were transferred into 
10 mL warm (37°C) IMDM containing 10% FCS. To prevent false positive results 9 x 
105 murine BaF3 cells were added and cells were rotated for 45 minutes at 37°C to allow 
cytokine release. IFN-γ release was immediately stopped by transferring cells into ice for 
5 minutes. After washing cells were resuspended in 78 µL ice-cold MACS-buffer and 
transferred into 96-well plates (Becton Dickinson). Captured IFN-γ was revealed by an 
APC-conjugated IFN-γ detection mAb (1:10; Miltenyi) and NK cells were marked with 
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FITC-conjugated anti-CD56 mAb and PE-labelled anti-CD16 mAb (both from BD 
PharMingen). 
Cells were analyzed using FACS Calibur and analysis was performed using CellQuest 
software (both from Becton Dickinson). 
 
 
7. Primary Materials 
 
All control and clinical samples were obtained with informed consent in compliance with 
the guidelines of the Ethical Committee of the University Hospital Basel, Switzerland. 
 
 
7.1 Healthy Donors 
 
To analyze NKG2D ligands in subpopulations of MNCs and activating receptors on NK 
cells compared to AML 22 PB samples and 7 BM samples of healthy donors were tested. 
To analyze NK cells phenotypically and functionally 13 PB samples and 6 BM samples 
of healthy donors were tested. 
 
 
7.2 AML Patients 
 
35 patients with AML were enrolled in the study. Twenty-eight patients had newly 
diagnosed untreated AML and 6 patients had a relapse of the disease (Table IV-1). The 
diagnosis and definition of AML subtypes M1-M7 was based on morphologic, 
cytogenetic and immunophenotypic criteria. The average blast content in PB was 52.8 ± 
5.2%. 
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Table IV-1, Characteristics of AML patients 
Patients Age, y AML subtype Status % Blasts per TNC 
HI 67 M1 ND 23 
JJ 37 M1 ND 11.2 
SH 73 M1 ND 84.3 
AG 53 M2 ND 73.3 
CA 39 M2 ND 55.4 
CL 67 M2 ND 73.5 
LE 44 M2 relapse 65.4 
PL 67 M2 ND nd 
SR 74 M2 relapse 58.9 
BH 46 M2 ND 3.1 
SC 69 M2 ND 88 
VP (patient B) 39 M3 ND 93.7 
BA 76 M4 ND 85 
DC 52 M4 ND 37.7 
EA (patient E) 68 M4 ND 76.5 
SJ 43 M4 relapse 26.5 
ZaC (patient D) 47 M4? ND 36.5 
BaT 57 pTx, M5b relapse 92 
CC (patient C) 43 M5 ND 93.5 
DS 28 M5b ND 37.4 
DR 31 M5b relapse 88.5 
GG 22 M5 ND 8 
SE 74 M5 ND - 
MU (patient A) 46 M5 ND 37.2 
Akt - M7 - 53.5 
TL 35 M7 ND 17.4 
WG 55 MD ND 65.3 
ZeC 50 MD ND 32.9 
OE 71 MD ND 0.7 
Z 54 MD ND 2.4 
BeT 68 2nd AML ND 78.2 
MI 66 2nd AML relapse 82.6 
RM 86 2nd AML ND 55.5 
KA 66 unknown ND 42.5 
RA 83 unknown ND 63.1 
TNC, total nucleated cells; ND, newly diagnosed; blasts of (Patients A-E) were used for in vitro killing 
assays; p, post. 
 
 
7.3 Patients after Hematopoietic Stem Cell Transplantation 
 (HSCT) 
 
28 patients who underwent an allogeneic HSCT were enrolled in this study (Table IV-2). 
High intensity conditioning consisted of cyclophosphamide at 60 mg/kg, followed by 
total body irradiation at 6 x 2 Gy, preceded in high-risk patients by additional etoposide 
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at 30 mg/kg. Prevention of GvHD in all patients was based on cyclosporine A (150-300 
mg/d) in a short course of methotrexate. 6 patients were part of a double-transplantation 
program. Median time to reach the neutrophil count of more than 500 per µL was 14 
days. On day 30, clinically evident acute GvHD grade was observed in 8 patients and 
grade II or III in 14 patients. On day +180, 19 patients were in complete remission, 
including 1 patient who had rejected the graft and achieved autologous reconstitution. 4 
patients died of a GvHD, 3 of infections, 1 of graft rejection and 1 of leukaemia relapse. 
 
Table IV-2, Characteristics of Patients Undergoing HSCT 
     GvHD  
UPN Age, y Diagnosis No. of HSCTs Engr day Day 30 Day 90 Status d +180 
603 32 CML 1 16 0 0 CR 
605 32 CML 1 14 II I CR 
671 16 B-ALL 1 8 I 0 CR 
727 23 B-ALL 1 14 II NA ✝ of GvHD 
730 17 AML 2 10 II II ✝ of infection 
767 44 AML 2 11 0 NA ✝ of relapse 
804 35 CML 1 20 II 0 Rejection/CR 
816 38 MM 1 12 II 0 CR 
818 42 SAA 1 14 I IV ✝ of GvHD 
820 40 AML 1 17 II 0 CR 
822 45 CML 1 11 I II CR 
831 50 CML 2 19 I II ✝ of infection 
832 44 AML 1 14 0 I CR 
834 27 CML 1 18 0 I CR 
845 17 SAA 1 11 0 0 CR 
852 35 CML 1 12 I 0 CR 
854 24 CML 1 13 I I CR 
860 19 AML 2 13 II I CR 
865 44 AML 2 11 II II CR 
872 36 AML 2 13 II I CR 
881 16 MDS 1 17 0 0 ✝ of rejection 
886 22 MDS 1 15 II I CR 
891 25 CML 1 13 III NA ✝ of infection 
893 23 AML 1 15 II III ✝ of GvHD 
903 22 SAA 1 15 I I CR 
904 42 CML 1 19 I I CR 
906 51 AML 1 13 III NA ✝ of GvHD 
908 22 B-ALL 1 17 II III CR 
UPN indicates unique patient number; Engr day, engraftment day indicates absolute neutrophil count > 
500/µL for 3 consecutive days; CML, chronic myeloid leukemia; CR, complete remission; B-ALL, acute 
lymphatic leukemia of B-cell type; NA, not applicable; ✝, died; MM, multiple myeloma; SAA, severe 
aplastic anemia; MDS, myelodysplastic syndrome. 
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V. Results 
 
1. Analysis of Expression and Regulation of Ligands for 
 NKG2D and NCRs 
 
Studies on the pattern of expression and the function of activating ligands represent the 
major part of this thesis. This is a novel field of research, since ligands for NKG2D 
receptor have been identified only recently13,55 and ligands for NCRs remain still 
unknown. The purpose of our studies was to investigate differences in cell surface 
expression of activating ligands by normal PB cells and malignant leukemic blasts and to 
understand the role of these ligands for leukemia recognition by NK cells. 
In the first part of our analyses, we performed a phenotypic analysis of normal and AML 
cells using mAbs specific against various NKG2D ligands and also novel reagents, based 
on recombinant NCRs, to detect the putative NCR ligands. 
In the second part of our analyses, we investigated conditions allowing to modulate 
ligand levels and we examined the role of activating ligands in the interaction with 
NKG2D receptor and NCRs on NK cells. 
 
 
1.1 ULBP Expression on PB Derived MNCs  
 
1.1.1  ULPB Molecules Are Expressed on B cells, Monocytes, 
Granulocytes and Platelets 
 
Previous studies addressing the ULBP expression by normal PB and BM MNCs detected 
ULBP transcripts13,109, but expression of ULBP proteins by hematopoietic cells had not 
been described. In order to identify ULBP expressing cells, full blood samples from 
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healthy volunteers were labelled with mAbs specific for hematopoietic lineages and for 
ULBP1, ULBP2 and ULBP3 (Figure V-1). 
 
 
Table V-1. Expression of ULBP Proteins by PB Cell Subpopulations 
 ULBP1 ULBP2 ULBP3 
 MFI ratio MFI ratio  MFI ratio  
 Mean ± SEM (Range) Mean ± SEM (Range) Mean ± SEM (Range) 
B cells 
n=19/10/19 
21.7 ± 2.8 (7.3-57.6) 10.4 ± 1.7 (4.3-23.5) 17.2 ± 4.3 (6.3-90.6) 
Monocytes 
n=22/12/22 
3.4 ± 0.5 (1.1-9.0) 2.1 ± 0.3 (1.1-5.2) 2.4 ± 0.3 (1.0-6.1) 
Granulocytes 
n=18/10/18 
2.8 ± 0.6 (1.0-9.5) 1.9 ± 0.3 (1.0-3.8) 2.1 ± 0.3 (1.0-5.2) 
Platelets 
n=3/3/3 
2.0 ± 0.2 (1.8-2.5) 7.8 ± 1.6 (4.7-9.6) 3.7 ± 0.2 (3.4-4.1) 
n indicates number of samples analyzed for ULBP1/ULBP2/ULBP3 expression 
 
 
Within lymphoid populations, all three ULBPs were highly expressed by B cells. In NK 
cells and T cells, however, they were absent. Among myeloid lineages, erythrocytes did 
not express ULBPs, while platelets expressed ULBP2 at a MFI ratio of up to 9.6, as well 
as low levels of ULBP1 and ULBP3 (Table V-1). On monocytes and granulocytes ligand 
levels were highly variable among several tested healthy donors. ULBPs were not 
detectable or were very low (MFI ratio < 2.0) in monocytes from 8 out of 22 donors and 
granulocytes from 10 out of 18 donors, but well pronounced in the rest of the donors.  
Ligand-positive monocytes always expressed all three ULBPs. ULBP1 was generally 
present at the highest levels with MFI ratios up to 9.5, and ULBP2 at lowest levels with 
MFI ratios of not more than 5.2 (Table V-1). 
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Figure V-1. ULBP molecules are expressed by PB cell subpopulations of normal donors.  FACS 
analysis of PB cells from healthy donors after staining with mAbs for ULBP1 (shaded area), ULBP2 (thin 
solid line) or ULBP3 (thick solid line) or with secondary FITC-labelled goat anti-mouse IgG alone (dotted 
line). PB cell subpopulations, indicated above each histogram, were distinguished with mAbs specific for 
lineage markers. Analysis of monocytes and granulocytes in two healthy donors with ULBP-positive (N1) 
and ULBP-negative (N2) phenotype is shown. 
 
 
1.1.2  mRNA Expression of ULBPs on B Cells and Monocytes 
 
To confirm the data obtained with flowcytometry, mRNA from cell lysates of FACS 
sorter-purified B cells, T cells and ULBP-positive monocytes was isolated and presence 
of ULBP transcripts was analyzed by quantitative real-time RT-PCR. ULBP1 message 
was detectable in B cells and monocytes of all donors. ULBP2 and ULBP3 transcripts 
were detectable in B cells of some donors but were below detection level in monocytes. 
Some T cell preparations were positive for ULBP mRNAs, although they were always 
phenotypically ligand negative (Figure V-2). The presence of ULBP messages in T cells 
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was unlikely due to contaminations, because analyzed preparations were highly pure 
(>97%). The ULBP signal was not detectable with less than 32 amplification cycles, 
indicating very low abundance. HPRT was used as an internal control. These data 
confirm previous reports with hematopoietic cell lines13,109 that levels of ULBP mRNA 
and protein does not always correlate. 
 
 
 
 
 
 
 
 
 
 
Figure V-2, mRNA Expression of ULBP1, ULBP2 and ULBP3. Real-time PCR analysis of ULBP1 
(U1), ULBP2 (U2) and ULBP3 (U3) mRNA levels in B cells, monocytes and T cells purified from 2-4 
donors, as indicated by the number of diamonds. The dotted line marks the upper limit of 40 amplification 
cycles. Threshold cycles; number of cycles at which the amount of PCR product passed the threshold of 
detection. C; control mRNA of HPRT. nd; not detectable 
 
 
 
1.2 MIC Ligands Expressed on B Cells and Monocytes 
 
Transcripts of MICs are found in low abundance in many cells, still surface expression of 
MIC protein is rare in adult healthy tissue. In contrast, MICs become upregulated in 
many epithelial tumor cells98. To analyze ULBP-positive monocytes and B cells as 
potential MIC expressing cells, blood from healthy donors was labelled with mAbs 
binding to MICA/B and with mAb binding to CD33 and CD19.  Same as for ULBPs, 
there was a variegated expression of MICA/B on monocytes among healthy donors. 
MICA/B were not detectable or very low (MFI ratio < 2) on monocytes from 4 out of 8 
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donors but present in the remaining donors at MFI ratio of up to 8.7 (Table V-2). On B 
cells of all tested individuals MICA/B expression was highly pronounced with MFI ratio 
of up to 85.2. 
These results show that MICA/B expression on B cells is markedly higher than on 
monocytes, which is in line with the data obtained for ULBPs. 
 
 
 Table V-2, Expression of MICA/B on Monocytes and B cells 
 MFI ratio 
 Mean ± SEM (Range) 
Monocytes (n=8) 3.1 ± 0.9 (1.2 – 8.7) 
B cells (n=7) 34.8 ± 8.6 ( 21.2 – 85.2) 
 
 
 
1.3 NKG2D Ligands Are Absent on in vitro Derived Dendritic 
 Cells 
 
Since B cells and monocytes were identified as the major ligand expressing population in 
PB, it was of interest whether ligand expression represents a common feature of antigen 
presenting cells. Thus ligand expression was also analyzed on DCs. For this purpose in 
vitro generated CD14+ monocytes were differentiated into iDCs using GM-CSF and IL-
4. After 3 days of incubation the culture contained 37% of CD1a+CD14- iDCs, which 
were lacking surface expression of ULBP1, ULBP3 and MICA/B (Figure V-3A). 
Addition of CD40L for 5 days resulted in 14.7% of mDCs displaying a CD1a+HLA-
DRbright phenotype expressing activation markers CD80, CD83 and CD86. ULBP1, 
ULBP3 and MICA/B were absent also on mDCs (Figure V-3B). 
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Figure V-3, Expression of Ligands on in vitro Generated DCs. FACS staining of ULBP1 (solid line), 
ULBP3 (thick solid line) and MICA/B (shaded area) or secondary FITC-labelled gtαms and gtαrat (dotted 
line) on (A) CD1a+CD14- iDCs and (B) CD80, CD83 and CD86 were stained on CD1a+HLA-DRbright 
mDCs and detected by secondary FITC-labelled gtαms mAb. 
 
 
This result shows that ULBP proteins are expressed on cell surface of B cells, platelets as 
well as monocytes and granulocytes from majority of donors. Except for platelets, which 
express ULBP2 at highest levels, the ligand which predominates in normal PB is ULBP1. 
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1.4 Validation of Soluble NCR Dimers 
 
So far viral hemagglutinins were shown to bind to NKp46 and NKp4456,84 but cellular 
ligands for NCRs have not yet been described. In order to identify activating cellular 
ligands the group or G. De Libero at the laboratory of Experimental Immunology 
(Department of Research, University Hospital Basle, Switzerland) generated dimers of 
recombinant proteins corresponding to extracellular domains of NKp30, NKp44 and 
NKp46. These soluble (s) NCRs were used in our study to identify potential ligand 
expressing cells.  
Several cell lines were used to test the binding capacity of NCR dimers. Complexes of 
sNKp30, sNKp44 and sNKp46 bound to THP-1 (MFI ratios of 3.3±0.5, 4.3±0.5 and 
5.3±0.9, respectively) and to HL60 (MFI ratios 2.7±0.2, 3.0±0.8 and 3.5±0.7, 
respectively), but not to K562-L cells (Figure V-4A). To confirm the specificity of the 
dimers, the ability of the sNCRs in inhibiting recognition of target cells was examined in 
killing assays and IFN-γ release assays. The sNCR cocktail strongly inhibited the killing 
of ligand expressing THP-1 and HL60 cells. In contrast, lysis of NCR ligand-negative 
K562-L cells remained unaffected by introducing sNCR dimers (Figure V-4B). 
For assessing the IFN-γ production by NK cells due to ligand recognition, NK cells were 
cocultured with THP-1 or HL60 cells for 44 hours. Release of IFN-γ was measured in 
culture supernatants using ELISA. As a positive control, NK cells were stimulated with 
IL-12 and IL-18 in the absence of target cells and produced 617.5 ± 69.4 ng/mL IFN-
γ (Table V-3). 
NK cells, cocultured with THP-1 cells, produced up to 15.77 ng/mL and 79.9 ng/mL 
IFN-γ in response to IL-2 and IL-12, respectively (Table V-3, Figure V-5A). Incubation 
of NK cells with HL60 cells resulted in release of 1.85 ng/mL and 39.2 ng/mL IFN-γ in 
IL-2 and IL-12, respectively. Lower IFN-γ production after incubation with HL60 cells is 
in line with lower expression levels of NCR ligands on HL60 cells than on THP-1 cells. 
Note that NK cells alone released markedly less IFN-γ than after coculture with target 
cells (Table V-3). 
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Figure V-4, Soluble NCR dimers recognize THP-1 and HL60 cells and inhibit their killing by NK 
cells. (A) FACS analysis of THP-1, K562-L and HL60 cells stained with sNKp30 (shaded area), sNKp44 
(thin solid line), sNKp46 (thick solid line) and anti-BirA1.4 mAb (dotted line) all detected by secondary 
FITC-labelled goat anti-mouse IgG. (B) Inhibition of NK cell-mediated killing of THP-1 and HL60 cells by 
sNKp30, sNKp44 and sNKp46 dimers. A calcein release-based cytotoxicity assay was used to determine 
the lysis of THP-1, K562-L and HL60 cells by NK cells at the indicated effector:target ratios. The killing 
assay was performed in the absence of sNCRs (black bars) or in the presence of a mixture of sNKp30, 
sNKp44 and sNKp46 at 5 µg/ml (grey bars), 20 µg/ml (open bars) and 50 µg/ml (hatched bars; to low to 
depict in THP-1) of each dimer. 
 
 
When sNKp30 and anti-NKG2D mAb were added to THP-1 cocultures, production of 
IFN-γ was reduced in a dose-dependent manner (Figure V-5B), while sNKp44 and 
sNKp46 were not interfering with the release of IFN-γ (data not shown). This suggests 
that primarily the ligands of NKG2D and NKp30 expressed by THP-1 cells are 
responsible for triggering the NK cell to release IFN-γ. 
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A  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure V-5, IFN-γ Production of NK Cells upon Coculture with THP-1 Targets. NK cells were 
incubated in the presence of THP-1 cells in IMDM, 10% FCS (medium; blue diamond, blue y-axis), IL-2 
(blue circle, blue y-axis) or IL-12 (red triangle, red y-axis) for 44 hours. IFN-γ release was measured in 
supernatants of cultures using ELISA. (A) Co-cultures were performed at different effector:target ratios 
(E/T). (B) Co-cultures were performed in IL-2 and IL-12 at effector:target ratio of 1:1 and 1:2, respectively. 
sNKp30 and anti-NKG2D mAb were added at different concentrations. 
 
 
 
These findings show that expression of NCR ligands on target cells confers to them the 
ability to activate of NK cells resulting in lysis of targets and in production of IFN-γ. This 
NK cell stimulation can be inhibited by masking the interaction of activating NCRs with 
their ligands using sNCR dimers, confirming the functionality of the reagents. 
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Table V-3, IFN-γ Release by NK Cells in Cocultures with Target Cells 
 NK cells + THP-1 NK cells + HL60 NK cells alone 
 
 
E/T 
IL-2  
n=5 
1:1 
IL-12  
n=3 
1:2 
IL-2 
n=1 
1:1 
IL-12 
n=2 
1:2 
IL-2 
n=3 
 
IL-12 
n=3 
IL-12, -18 
n=6 
IFN-γ 8.09 ± 1.98 59.9 ± 17.1 1.85 39.2 1.5 ± 0.12 5.97 ± 2.59 617.5±69.4 
ng/mL (5.18-15.77) (25.8-79.9) - (38.2-40.2) (1.3-1.7) (0.92-9.5) (370-900) 
Cultures were performed in IL-2 (100U/mL), IL-12 (10U/mL) or in IL-12 and IL-18 (10U/mL and 
100ng/mL, respectively). Numbers are showing mean values (ng/mL) ± SEM and (range). E/T indicates 
effector to target ratios. 
 
 
 
1.5 Expression of NCR Ligands on B Cells and Monocytes 
 
Using FACS, sNCR dimers were found to bind to monocytes and B cells of healthy 
donors. Similarly to ULBPs, not all individuals had ligand positive monocytes. Putative 
NCR ligands were not detectable or were very low (MFI ratio < 2.0) in monocytes from 4 
out of 11 donors (Table V-4). 
These results show that similar to ULBPs putative ligands for NCRs are expressed on B 
cells and monocytes in PB of healthy donors and on tumor cell lines THP-1 and HL60.  
 
 
Table V-4, Binding of sNCRs to B Cells and Monocytes in Healthy PB 
 B cells Monocytes 
 MFI Ratio MFI Ratio 
 Mean ± SEM Range Mean ± SEM Range 
NKp30 Ligand 
n=7/8 
25.1 ± 3.5 (11.8-43.1) 9.6 ± 5.8 (1.3-48.8) 
NKp44 Ligand 
n=9/10 
32.5 ± 7.6 (14.1-69.8) 6.0 ± 2.3 (1.5-19.1) 
NKp46 Ligand 
n=12/13 
26.2 ± 7.1 (5.0-60.0) 2.8 ± 0.7 (1.1-7.7) 
n indicates number of B cell/monocyte samples analyzed 
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1.6 Expression of NCR and NKG2D Ligands Is Low on AML 
 Blasts 
 
To analyze ULBP and NCR ligand expression in AML, PB cells from 30 AML patients 
(Table IV-1) were stained with mAb against CD45 to distinguish CD45dim leukemic 
blasts from CD45bright residual normal cell populations (Figure V-6).  
 
 
 
 
 
 
 
 
 
 
 
Figure V-6, Gating of AML Blasts in FACS Analysis. To distinguish AML blasts from residual normal 
cells, blood samples were stained with anti-CD45 mAb. Cell populations were gated according to forward 
(FCS), sideward (SSC) scatter and to CD45 expression level. FACS analysis of one healthy donor and two 
AML patients (AML1, AML2) are depicted. The left panel shows the gating of mononuclear cells (MNC). 
The right panel represents expression levels of CD45 on AML blasts (Bl) and on residual normal cells (RN) 
in AML patients. 
 
 
CD45bright B cells of AML patients expressed NKG2D and NCR ligands at normal high 
levels (Table V-5 and -6) as was seen with B cells of healthy donors (Table V-1,-2 and -
4). Furthermore, NKG2D and NCR ligands were found on CD45bright patients’ monocytes 
and granulocytes at variable levels (Figure V-8, Table V-5), resembling the variability of 
ligand cell surface density observed in healthy donors (Table V-1,-2 and -4). However, 
ULBP-low phenotype of CD45bright cells was observed in only 6 patients of the cohort, 
while ULBP expression by CD45dim blasts was very low with a MFI ratio < 2.0 in 23 out 
Donor AML 1 AML 2 
MNC MNC 
Bl 
RN 
Bl 
RN 
MNC 
FSC
CD45-PerCP
SS
C
 
RESULTS 
63 
of 30 patients (Figure V-7). In addition, in 3 among the remaining 7 patients, only 6-37% 
of all blasts were ULBP positive. 
 
Table V-5, Expression of ULBPs and Putative Ligands for NCRs on B Cells of AML Patients 
 ULBP1 
(n=27) 
ULBP2 
(n=13) 
ULBP3 
(n=27) 
NKp30L 
(n=7) 
NKp44L 
(n=9) 
NKp46L 
(n=12) 
15.5 ± 1.6 7.6 ± 1.4 10.6 ± 1.2 19.3 ± 1.6 21.4 ± 4.0 22.0 ± 3.6 
MFI ratio 
(4.5-32.7) (3.8-20.8) (3.2-28.7) (14.7-28.4) (8.1-42.9) (9.7-45.1) 
Numbers correspond to mean values ± SEM and (Range); L, ligand. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure V-7. Low ULBP and NCR ligand expression in AML Blasts. PB samples of AML patients were 
stained with mAbs against lineage-specific markers and anti-CD45 mAbs to distinguish CD45dim leukemic 
blasts from CD45bright residual normal monocytes and granulocytes. ULBP1, ULBP2 and ULBP3 (left 
panels) were measured with specific mAbs on monocytes (open diamonds), granulocytes (open circles) and 
blasts (black diamonds). Binding of sNKp30, sNKp44, and sNKp46 dimers (right panels) to monocytes 
(open diamonds), granulocytes (open circles) and blasts (black diamonds). Mean values are indicated as 
horizontal bars. * p< 0.05; ** p< 0.005. 
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MICA/B expression was absent on blasts of 6 out of 9 patients (Table V-6). Similarly to 
NKG2D ligands, CD45dim AML blasts displayed a very low sNKp30, sNKp44 and 
sNKp46 dimer-binding capacity (MFI ratio < 2.0) in 10 out of 12 analyzed patients 
(Figure V-7). 
 
 
Table V-6, MIC Molecules in AML Patients 
 CD45dim Blasts CD45bright B Cells CD45bright Monocytes 
Average ± SEM 1.8 ± 0.3 33.6 ± 5.6 6.6 ± 2.6 
(Range) (1.0-3.6) (15.3-64.0) (2.0-26.8) 
Values represent average mean fluorescence intensities of MIC proteins detected on blasts and residual 
MNCs of 9 analyzed AML patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure V-8, Ligand Expression in AML Subtypes. ULBP and NCR ligand expression classified 
according to AML subtype. PB cells of patients with AML of subtypes M1-M7 were stained as described 
in the legend to Figure 3 and CD45dim leukemic blasts were analyzed for the expression levels of ULBP (A) 
and NCR ligands (B). *; only 20% of blasts were ULBP1 and ULBP3 positive. 
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These results demonstrated that AML blasts in the majority of patients display 
negative/low surface levels of ligands for NKG2D and NCRs. Analysis of ligand 
expression in terms of AML FAB classification revealed that 5 out of 6 patients with 
monocytic M5 and 1 out of 2 patients with megakaryocytic M7 had ULBP-positive 
blasts. Among other subtypes, only 1 patient with M1 had ULBP-positive blasts, which 
however constituted only 20% of his blast population (Figure V-8). This suggests that 
ligand expression by myeloid blasts is more frequent when leukemic transformation takes 
place at later stages of differentiation, although investigation with a larger group of 
patients is needed to conclude about the association of NKG2D ligand expression and the 
subtype of myeloid leukemia. 
 
 
1.7 NKG2D and NCR Ligands Are Absent on BM Progenitors 
 
To investigate further whether ligand levels may be related to the differentation stage of 
myeloid cells, NKG2D and NCR ligand expression by normal BM CD34+ hematopoietic 
progenitors and precursors committed to the myeloid lineages were examined (Figure V-
9A-B, Table V-7). 
 
 
Table V-7, MIC Expression in Healthy BM 
 CD34+CD33- CD34+CD33+ CD34-
CD33+CD14- 
CD34-
CD33+CD14+ 
Average ± SEM 1.6 ± 0.36 1.5 ± 0.20 3.8 ± 1.30 7.4 ± 1.41 
(Range) (1.1-2.3) (1.2-1.9) (1.7-6.2) (6.0-10.3) 
Values represent average mean fluorescence intensities of MIC proteins detected in 3 analyzed BM 
samples. 
 
 
Early CD34+CD33- progenitors and also CD34+CD33+ cells displayed very low surface 
levels of NKG2D and NCR-specific ligands (MFI ratio < 2.0). CD34- myeloid cells, both 
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CD33+CD14- and mature CD33+CD14+ monocytes present in the BM, expressed the 
ULBPs, with a strong prevalence of ULBP1 compared to ULBP2 and ULBP3, and 
displayed MICA/B and all the NCR ligands on their surface. These results demonstrate 
that cell surface ULBPs, MICs and NCR ligands become expressed upon loss of the early 
hematopoietic marker CD34 and acquisition of the myeloid markers CD33 and CD14. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure V-9, ULBP and NCR ligand expression is low on CD34+ cells and well pronounced on myeloid 
progenitors in normal BM. ULBP expression was determined by FACS in the indicated BM 
subpopulations. (A) BM staining with ULBP1-specific mAbs (thick line) or control secondary FITC-
labelled goat anti-mouse IgG alone (thin line). (B) BM staining from 3 healthy donors with mAbs to 
ULBP1, ULBP2, ULBP3, as well as sNKp30, sNKp44 and sNKp46 dimers. 
 
 
 
1.8 Progenitors and Monocytes Are Protected from Killing by 
 Autologous NK Cells 
 
To investigate whether expression of ligands for NKG2D and NCRs renders healthy cells 
susceptible to NK mediated killing, monocytes and autologous NK cells were purified by 
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magnetic labeling from PB of a healthy donor. Monocytes and NK cells were cultured 
separately for 2 days in the presence of myeloid growth factors and IL-2, respectively. 
Next, autologous killing was assessed by a chromium release assay. Killing of autologous 
monocytes was only 11% at an effector to target ratio of 10:1. When inhibitory signaling 
was blocked by anti-MHC class I mAbs killing was increased to 26%. Killing that was 
measured after adding control anti-MHC class II mAbs was always below lysis detected 
after adding anti-MHC class I mAbs (Figure V-10A). 
CD34+ progenitor cells purified from mobilized PB by magnetic labeling were cultured 
for 3 days in FL and Tpo. Killing of CD34+ progenitor cells was assessed in a chromium 
release assay using autologous NK cells. Lysis of progenitors was not detectable at tested 
effector to target ratios ranging from 5:1 down to 0.6:1 (data not shown). Blocking of 
inhibitory signaling by anti-MHC class I mAbs induced 4% killing. However, addition of 
control anti-MHC class II mAbs induced the same cell lysis (Figure V-10B). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure V-10, Killing of Monocytes and CD34+ Progenitors by Autologous NK cells. (A) Monocytes 
cultured for 2 days in myeloid growth factors were analyzed at different effector to target ratios in 
cytotoxicity assay using autologous NK cells cultured for 2 days in IL-2. (B) CD34+ progenitors cultured 
for 3 days in FL and Tpo were assessed for killing at an effector to target ratio of 2.5:1 by autologous NK 
cells cultured for 2 days in IL-2. Killing was measured without addition of mAbs (black bars), with 
addition of anti-MHC class I mAb (10µg/mL; grey bars) or addition of control anti-MHC class II mAb 
(10µg/mL; open bars). Values represent one experiment carried out in triplicates. 
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Taken together these results show that ligand positive monocytes are protected from 
killing by autologous NK cells through engagement of inhibitory NK cell receptors. 
Blocking of inhibitory signaling with anti-MHC class I mAbs induced killing of 
monocytes, whereas killing of progenitors remained very low, indicating that cells 
lacking ligands for triggering NK cell ligands are not recognized as target cells. 
 
 
1.9 In Vitro Upregulation of ULBP1 and NCR Ligands 
 
1.9.1 ULBP1 and NCR Ligand Upregulation on Monocytes 
 
To understand the variable ULBP and NCR ligand expression on monocytes and 
granulocytes from different individuals, ULBP-negative CD14+ monocytes were purified 
from healthy donors by magnetic labeling. Isolated cells were maintained in culture by 
myeloid growth factors (GFs; FL, SCF and GM-CSF). Furthermore, various cytokines 
(IFN-α, IFN-γ, IL-1β and TNF-α) and LPS, all known to activate monocytes161,167, were 
added to the cultures. Analysis of ULBP surface expression after 3 days of culture 
revealed that IFN-α, IL-1β, TNF-α and LPS used singly or in combination were not 
effective in inducing expression of ULBPs and putative NCR ligands (Table V-8).  
However, ULBP1 was selectively expressed in monocytes cultured with myeloid growth 
factors. ULBP1 level was further increased when cells were additionally activated with 
IFN-γ(Figure V-10A). ULBP2 and ULBP3 were unaffected by any of these conditions 
(data not shown). Ligands for NCRs were also upregulated in response to myeloid growth 
factors and IFN-γ (Figure V-10A). The modulation of ULBP1 and NCR ligands with 
IFN-γ was dose-dependent and gradually increased within three days of incubation 
(Figure V-10B). 
These experiments indicate that the presence of ligands for NKG2D and NCRs may 
correspond to the activation or maturation state of monocytes, since their expression can 
be induced by myeloid growth factors and IFN-γ. ULBP2 and ULBP3 seem to be 
regulated by a different pathway. 
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Figure V-10, Upregulation of ULBP1 and Putative NCR ligands in PB Derived CD14+ Monocytes. 
(A) FACS analysis of anti-ULBP1 mAb (black bars), sNKp30 (grey bars) and sNKp46 (open bars) surface 
binding by freshly isolated (ex vivo) CD14+ monocytes. Monocytes were subsequently cultured for 3 days 
in IMDM, 10% FCS (medium) or with GFs (SCF+FL+GM-CSF;) and IFN-γ  as indicated. Results 
represent mean values ± SEM of 3 independent experiments. (B) Myeloid CD33+ cells derived in vitro 
from CD34+ progenitors were incubated with IFN-γ before measuring anti-ULBP1 mAb (black diamond), 
anti-ULBP3 mAb (black quadrant), sNKp30 (black triangle), sNKp44 (asterix) and sNKp46 (white circle) 
surface binding by FACS. Left panel shows different time points of FACS analysis of cells cultured in 100 
U/ml IFN-γ. Right panel shows FACS analysis of cells cultured for 72 hours in different concentrations of 
IFN-γ. 
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Table V-8, Expression of Ligands for NKG2D and NCRs on Monocytes after in vitro Culture 
 ULBP1 ULBP2 ULBP3 sNKp30 sNKp44 sNKp46 
medium 1.8* 1.1* 1.1 3.6±1.1** 3.3±1.0** 10.9±4.7** 
GFs 3.1±0.5# 1.2 1.2 3.9±1.6** 4.4±2.3** 14.6±6.0** 
GFs, IFN-γ 4.5±0.6# 1.1 1.1 5.7±1.2** 6.2±1.8** 11.1±5.0** 
GFs, IFN-α 1.7* 1.1 1.1 3.9* 3.5* 9.8* 
GFs, TNF-α 2.9 1.1 1.1 - - - 
GFs, IFN-γ/α, TNF-α 2.4 1.2 1.1 - - - 
GFs, IFN-γ, IL-1β, LPS 5.0* - - - - - 
GFs include FL, SCF and GM-CSF. If not otherwise indicated experiments were only done once. Numbers 
correspond to mean values obtained from * 2, ** 3 or # 4 experiments. 
 
 
 
1.9.2 ULBP1 and NCR Ligands Are Upregulated upon Myelomonocytic 
 Differentiation of BM Progenitors 
 
To confirm that ligand expression is upregulated upon myelomonocytic 
differentiation, purified BM-derived CD34+ cells were cultured in the presence of 
myeloid growth and differentiation factors, SCF, FL and GM-CSF. After 7 days, cultures 
consisted of about 84.5% ± 1.7% CD34-CD33+ cells containing 16.5% ± 2.8% CD14 
expressing cells (Figure V-11A). Myeloid cells generated in vitro from the ligand-
negative hematopoietic progenitors expressed ULBP1 and NCR ligands (Figure V-11B). 
The surface expression of ULBP1 and NKp30 ligand was further upregulated upon 
addition of IFN-γ, also used in combination with LPS and IL-1β Expression of ULBP2 
and ULBP3 was not enhanced under these conditions. These results show that ULBP1 
and ligands for NKp30, NKp44 and NKp46 are induced by the myeloid growth and 
differentiation factors and in response to IFN-γ, whereas signals upregulating expression 
of ULBP2 and ULBP3 on CD33+ cells remain unknown. 
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Figure V-11, ULBP and NCR ligand surface expression increases upon myeloid differentiation of 
normal BM progenitor cells in vitro. (A) Purified CD33+/-CD34+ BM progenitors were cultured with GFs 
(FL, SCF, GM-CSF) and analysed for CD34, CD33 and CD14 expression by FACS. Proportion of CD14+ 
myeloid cells is displayed on CD33+ gated cells. (B) FACS analysis of ULBP1, ULBP2 and ULBP3 
surface expression and sNKp30, sNKp44 and sNKp46 binding by freshly isolated CD34+ cells (black bars) 
and after 7 days of culture with GFs (SCF+FL+GM-CSF; grey bars), GFs together with IFN-γ (open bars) 
or together with IL-1β, LPS and IFN-γ (hatched bars) for an additional 3 days. Results represent the mean ± 
SEM of 3 BM samples. 
 
 
 
1.9.3 Upregulation of Ligands for Activatory NK Cell Receptors on 
 AML Blasts Increases NK Cell Mediated Killing 
 
Next, it was investigated whether FL, SCF, GM-CSF and IFN-γ can upregulate the 
triggering ligands on AML blasts in vitro. Following 4 days in culture, ULBP1 and NCR 
ligand expression were increased on blasts of 2 out of 5 patients with initially low as well 
as high ligand levels (Figure V-12A). As already found with normal cells, ULBP2 and 
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ULBP3 remained unchanged on leukemic blasts. To test whether an increase in ULBP1 
and NCR ligand levels raises the susceptibility of AML blasts to NK cell-mediated 
cytolysis chromium release assays were performed (Figure V-12B). The sensitivity to 
killing decreased following treatment with FL, SCF, GM-CSF and IFN-γ, most likely due 
to a protective effect of HLA class I molecules which were upregulated in response to 
IFN-γ two- to fourfold. However, when blasts were preincubated with antibodies 
preventing interactions of HLA class I ligands with the inhibitory receptors, the killing of 
blasts with upregulated ligand expression in response to growth factors and IFN-γ was 
markedly enhanced from 15% and 25% to about 30% and 45%, respectively.  
To confirm inhibition of allogeneic NK cells through HLA class I molecules on the 
surface of blasts, HLA alleles of donors and patients patients were compared (Table V-9). 
 
 
Table V-9, HLA Types of AML Patients and Allogeneic NK Cells Used in Killing Assays 
Patient A A3 A29 B38 B44 Cw16  
PBNK VII A2 A32 B8 B40 Cw2 Cw7 
Patient B A2 A32 B41 B27 Cw1 Cw17 
PBNK IX A2  B40 B51 Cw2 Cw3 
Patient C A1 A26 B55 B57 Cw3 Cw6 
PBNK X A2 A29 B18 B44 Cw7 Cw16 
Patient D A2 A24 B7 B35 Not done 
PBNK VII A2 A32 B8 B40 Cw2 Cw7 
Patient E A2 A3 B51 B60 Cw3 Cw4 
PBNK IX A2  B40 B51 Cw2 Cw3 
Overlapping HLA molecules, that can inhibit NK cell activation, of AML patients and allogeneic NK cells 
are marked as bold. PBNK; PB derived NK cells. 
 
 
Killing of blasts from patient A could not be increased by masking inhibitory signalling 
through MHC class I molecules. This was in line with the fact that cells from patient A 
do not engage the inhibitory KIRs present on the allogeneic NK cells used in the killing 
assay (Table V-9). Killing of blasts from patients B to E was markedly increased when 
engagement of inhibitory signals in NK cells was blocked by anti-MHC class I mAb.  
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Figure V-12, Upregulation of ULBP and NCR ligands increases the susceptibility of AML blasts to 
NK cell-mediated cytotoxicity. (A) Upregulation of ULBP and NCR ligands on AML blasts from five 
patients. Blasts were cultured for 4 days in medium only (black bars) or with GFs (FL+SCF+GM-CSF) and 
IFN-γ (open bars) before FACS analysis. (B) Killing of blasts cultured for 4 days without (medium) or with 
GFs and IFN-γ was determined with or without blocking of HLA class I molecules with mAb (10µg/mL), 
as indicated. NK cells derived from healthy donors were used at the indicated effector:target ratios. nd, not 
done. 
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Analysis of HLA typing revealed that in patients B and C there was at least one match in 
HLA alleles compared to the allogeneic NK cells used in the killing assays. In patient E 
where masking of inhibitory signalling resulted in the most pronounced increase of 
cytotoxicity at least two HLA alleles matched compared to the healthy NK cells (Table 
V-9).  
Interestingly, blasts from patient E were highly killed after blocking HLA class I 
molecules although ULBP1 and NCR ligands were only expressed at very low levels. 
This indicates that there might be other triggering ligands present, such as the very 
recently identified RAET1E and RAET1G115.Killing of blasts from patients B and C was 
also tested with freshly isolated NK cells from healthy donors, cultured for 4 days in IL-2 
(Figure V-13B). Importantly, blasts from patient B were highly killed without blocking of 
MHC class I molecules, although at least one HLA allele matched with the allogeneic 
NK cells used (PBNK X see Table V-9).  
Cytotoxicity of NK cells was again improved when blasts from patient B had been treated 
with myeloid growth factors and IFN-γ. There was no increase in killing of growth factor 
and IFN-γ treated blasts from patient C, though. This might be explained by the fact that 
blast from patient C already expressed ligands ex vivo. 
To analyse whether enhanced killing of blasts cultured with growth factors and IFN-γ 
was dependent on ligand upregulation, blocking with anti-NKG2D mAb was performed. 
Lysis of AML blasts from patient B and C was reduced from 30% to 23% and from 46% 
to 26%, respectively, when NKG2D was masked by specific mAb (Figure V-13A). 
These results indicate that enhanced levels of ligands for the activating receptors NKG2D 
and NCR can increase the recognition of AML blasts by NK cells. 
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Figure V-13, Killing of AML Blasts after Ligand Upregulation is Partly NKG2D Dependent. 
Leukemic blasts of patients B/C were cultured for 4 days in medium only or with GFs (FL+SCF+GM-CSF) 
and IFN-γ. NK cell susceptibility was then assessed using (A) PHA/feeder cell/IL-2 activated healthy NK 
cells and (B) freshly isolated healthy NK cells cultured for 4 days in IL-2. To block inhibitory signals anti-
MHC class I mAb (10 µg/mL) was added, as indicated. (A) Killing assays were performed at effector:target 
ratio of 10:1. Blocking with anti-NKG2D mAb (20 µg/mL) was performed, as indicated. 
 
 
 
2. Characterization of NK Cells in AML Patients 
 
The studies described above demonstrated that AML blasts from majority of patients at 
the onset or relapse of leukaemia display very low levels of ligands for the activatory NK 
cell receptors. This low ligand expression may be responsible for the poor 
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immunogenicity of leukemic blasts. Next, we investigated the expression of MHC class I 
ligands for inhibitory receptors and the number and phenotype of residual NK cells in 
AML. 
 
 
2.1 Evaluation of PB Cell Subpopulations in AML Patients 
 
To analyze the number of residual healthy hematopoietic lineages in AML patients whole 
blood of untreated patients at time of diagnosis or relapse was analyzed by FACS and 
compared to healthy donors. Distinct residual CD45bright cell populations were detected 
by specific lineage markers.  
Percentage of CD56+CD3- NK cells in total MNCs was decreased in AML in average 2.5 
fold compared to healthy donors. Furthermore, in 11 out of 24 patients NK cells were 
below 1% of total nucleated cells (TNCs) with one patient lacking NK cells. In contrast, 
NK cells among 11 donors were only in one donor below 1% of TNCs (Table V-10). 
 
 
Table V-10, PB Subpopulations in AML Patients 
 % per MNC % per TNC 
 Mean ± SEM (Range) Mean ± SEM (Range) 
NK cells     
Donors (n=11) 7.0 ± 1.5 (1.2-20.3) 2.6 ± 0.5 (0.3-6.7) 
AML Patients (n=24) 2.8 ± 0.6* (0-11.6) 2.0 ± 0.5 (0-8.8) 
T cells     
Donors (n=11) 58.2 ± 3.1 (43.6-75.9) 21.7 ± 1.9 (11.6-34.2) 
AML Patients (n=24) 27.3 ± 4.9** (3.9-87.8) 18.3 ± 3.4 (2.8-57.6) 
B cells     
Donors (n=15) 7.5 ± 0.7 (2.5-14.0) 2.9 ± 0.3 (1.3-4.9) 
AML Patients (n=25) 6.2 ± 2.0 (0-43.8) 3.8 ± 1.1 (0-17.4) 
Monocytes     
Donors (n=15) 18.9 ± 2.8 (4.2-44.0) 6.7 ± 0.8 (1.8-12.2) 
AML Patients (n=25) 10.3 ± 3.0* (0-56.5) 8.1 ± 2.5 (0-51.1) 
* p < 0.05 compared with healthy donors; ** p < 0.01 compared with healthy donors. 
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CD3+CD56- T cells and CD33bright monocytes in AML were also decreased 2.1 and 1.8 
fold, respectively (Table V-10). Moreover, T cells in 10 among 24 AML patients were 
decreased below 10% of TNCs and monocytes in 7 out of 25 patients comprised less than 
1% of TNCs. 
CD19+ B cells in MNCs of AML patients were present at normal levels. However, B 
cells in 9 out of 25 patients were decreased to levels below 1% of TNCs with one patient 
lacking B cells. 
These results showed that there was a significant decrease in NK cells, T cells and 
monocytes of AML patients, with 18 out of 25 AML patients having deficient numbers of 
either NK cells, T cells, B cells or monocytes and with 10 out of 25 patients being 
affected in more than only one lineage. 
 
 
2.2 Expression of MHC Class I Molecules on AML Blasts 
 
To analyze MHC class I ligands in AML, PB cells from 22 AML patients were stained 
with mAbs specific against HLA-A,B,C and expression levels were tested on CD45dim 
leukemic blasts and CD45bright residual MNCs. 
Healthy donors expressed HLA-A,B,C at a mean MFI ratio of 232.6 ± 19.9, whereas in 
AML patients MHC class I molecules were significantly decreased with MFI ratios of 
115.1 ± 26.1 and 168.6 ± 27.0 in blasts and residual MNCs, respectively (Figure V-14).  
These results indicate that leukemic blasts can escape through engagement of inhibitory 
KIRs from recognition by NK cells unless activating ligands are expressed at sufficient 
levels to overcome the inhibitory signalling. However, our results have shown that 
expression of ULBP ligands and putative ligands for NCRs on blasts is very low, 
suggesting that inhibiting signals generally prevail in AML blasts. 
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Figure V-14, HLA-A,B,C Expression in AML. PB samples of AML patients were stained with anti-
HLA-A,B,C mAbs on CD45dim blasts (black diamonds) and on CD45bright residual MNCs (open diamonds). 
MFI ratios were compared to MHC class I expression levels on MNCs from healthy donors (open circles). 
Mean values are indicated as horizontal bars. * p < 0.05; ** p < 0.005. 
 
 
 
2.3 Activating Receptors Are Expressed Normally on NK Cells 
 from AML Patients 
 
Expression levels of NKG2D and NKp46 receptors were measured on CD56+CD3- NK 
cells within CD45bright residual healthy cells of fresh PB from AML patients using FACS. 
NKG2D expression on NK cells of AML patients was similar to receptor levels measured 
on NK cells of healthy donors with MFI ratios of up to 14.0 (Table V-11). Analysis of 
NKp46 receptor levels revealed no decrease on NK cells of AML patients, either, with 
MFI ratios of up to 18.2 (Table V-11). 
NK cells were further analyzed by FACS for the expression of CD16, an activating Fcγ 
receptor, which is expressed on majority of NK cells16. In AML the proportion of CD16+ 
NK cells was decreased to 63.4% ± 7.3% compared to healthy donors with 81.8% ± 3.6% 
CD16+ NK cells (Table V-11). In 5 out of 22 AML patients only 0.1-9.7% of NK cells 
expressed CD16. 
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Table V-11, Expression of Activating Receptors on NK Cells 
 NKG2D NKp46 CD16 
 MFI Ratio MFI Ratio % of NK cells 
 Mean ± SEM (Range) Mean ± SEM (Range) Mean ± SEM (Range) 
Donors  
(n=9/11/10) 
6.8 ± 0.7 (4.2-10.9) 10.0 ± 0.9 (6.1-17.2) 81.8 ± 3.6 (51.7-
92.6) 
AML Patients 
(n=21/18/22) 
6.8 ± 0.7 (2.7-14.0) 9.6 ± 1.1 (2.7-18.2) 63.4 ± 7.3 (0.1-92.7) 
n indicates the number of PB samples analyzed for NKG2D/NKp46/CD16 
 
 
These results show that the activating receptors NKG2D and NKp46 are expressed at 
normal high levels on NK cells of AML patients. However, the proportion of CD16+ NK 
cells is decreased in 5 out of 22 AML patients. This decline may result in diminished 
NK-cell mediated target lysis, since CD16+ NK cells are more cytotoxic than CD16- NK 
cells21. Cytokine production which is induced through stimulation of NKG2D and 
NCRs54,85 and is a main function of CD16dim/- NK cells should not be affected25. 
 
 
 
3. Characterization of NK Cells in Patients after 
 HSCT 
 
The post-HSCT immunity is recognized as an important determinant of the clinical 
outcome. Recent progress in understanding the mechanism of NK cell cytotoxicity 
against tumor tissue has initiated interest in the anti-leukemic function of these cells. So 
far, little has been known about the reconstitution of NK cell compartment after HSCT. 
Therefore, our studies addressed the efficiency of NK cell development from donor-
derived stem cells as well as phenotypic and functional properties of NK cells in the early 
period after allogeneic HSCT. 
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3.1 NK Cell Reconstitution in Transplanted Patients 
 
To monitor the recovery of NK cells after allogeneic HSCT, the number of CD56+CD3- 
cells was measured by FACS analysis of PB and BM samples on days 7, 14, 30, 90 and 
180 after HSCT. NK cells were detectable already on day 7, although at very low 
numbers, and therafter their number increased rapidly (Table V-12). In PB, the frequency 
of CD56+CD3- cells returned to normal at 3 months (3.09% ± 0.73% versus 3.31% ± 
0.74% in healthy donors), although the absolute number at that time was still below 
normal (8.20 ± 1.83 versus 19.46 ± 4.35 x 104/mL). The recovery of NK cells in the BM 
was faster than in PB. These data show a rapid reconstitution of NK cells in patients after 
allogeneic HSCT. 
 
 
Table V-12, NK Cell Content in PB and BM of Patients after Allogeneic HSCT 
 PB NK Cells  BM NK Cells 
 % TNCs x 10-4/mL  % TNCs x 10-4/mL 
Donors 3.31 ± 0.74 19.46 ± 4.35  0.76 ± 0.24 11.08 ± 3.01 
Patients after HSCT      
Day 7 (n = 5/0) 1.98 ± 1.6 0.50 ± 0.34**  ND ND 
Day 14 (n = 16/8) 1.84 ± 0.44* 6.05 ± 1.82**  0.97 ± 0.30 8.53 ± 2.13 
Day 30 (n = 16/14) 1.64 ± 0.22* 10.62 ± 2.30*  0.99 ± 0.30 8.87 ± 3.47 
Day 90 (n = 15/12) 3.09 ± 0.73 8.20 ± 1.83*  1.18 ± 0.36 9.77 ± 2.66 
Day 180 (n = 9/7) 3.08 ± 0.64 12.72 ± 2.15  1.35 ± 0.31 13.68 ± 5.00 
All numbers are expressed as mean ± SEM; % TNCs is percent of total nucleated cells. n indicates number 
of PB/BM samples analyzed at each time point; ND, not done. 
* p < 0.05 compared with healthy controls. 
** p < 0.005 compared with healthy controls. 
 
 
 
 
RESULTS 
81 
3.2 Phenotypic Analysis of NK Cells after Allogeneic HSCT 
 
To characterize the NK cell population that develops after allogeneic HSCT, phenotypic 
analysis of cell-surface markers that define the maturation and activation stages of human 
NK cells was performed. Most remarkably, the CD56dimCD16bright NK cells, which 
represent the predominant subset of mature cytotoxic NK cells in normal PB, were 
strongly reduced. Conversely, there was an accumulation of cells with a CD56brightCD16-
/dim phenotype (Figure V-15).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure V-15, Phenotypic Characteristics of NK Cells after HSCT. (A) FACS profile of CD56brightCD16-
/dim and CD56dimCD16bright subpopulations of NK cells in a patient after HSCT compared with the healthy 
donor. (B) Percentage of CD56brightCD16-/dim and CD56dimCD16bright NK cell subpopulations and expression 
of NK cell markers Nkp46, CD161, HLA-DR and CD69 in patients after HSCT and healthy donors (N) is 
shown (mean ± SEM). Time after transplantation is indicated. *P < .05, **P < .005 compared with healthy 
donors. 
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The ratio of CD56dimCD16bright versus CD56brightCD16-/dim subsets after HSCT was 1.3 to 
1.9 compared with 7.4 in control PB. This strong skewing persisted for as long as 6 
months in all except for 2 patients. Of other analyzed markers, expression of CD161 
present on both immature and mature NK cells191 was reduced, whereas NKp46, the 
major NCR selectively expressed by NK cells78, was at normal levels (Figure V-15B). 
Expression of activation markers CD69 and HLA-DR, was significantly increased on 
both CD56brightCD16-/dim and CD56dimCD16bright cell subsets. Thus, despite rapid 
numerical recovery of NK cells, the phenotypic profile reflects distinct abnormalities in 
NK cell differentiation after HSCT. 
 
 
3.3 IFN-γ Production by NK Cells from Transplanted Patients 
 
To examine the functional properties of the NK cell compartment during early recovery 
after HSCT, CD56brightCD16-/dim and CD56dimCD16bright NK cell subsets were purified 
from patients’ PB on day 30. Due to low yields (< 2x104 CD56brightCD16-/dim and < 105 
CD56dimCD16bright cells) isolated cells were subjected to proliferation in vitro by 
restimulation with feeder cells and PHA in IL-2 medium. Their ability to produce IFN-γ 
was examined in response to specific stimulation with IL-12 and IL-18. 
Abundant IFN-γ production was seen with the CD16-/dim subset with 55% to 85% IFN-γ+ 
NK cells, whereas stimulation of CD16bright cells resulted in 25% to 55% of IFN-γ+ cells 
(Figure V-16). 
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Figure V-16, IFN-γ Production by NK Cell Subsets Derived from Patients after HSCT. CD16-/dim and 
CD16high cells were purified, expanded, and stimulated with IL-2 (open bars) or IL-12 and IL-18 (black 
bars). Frequency of INF-γ+ NK cells was determined by MACS IFN-γ secretion assay. Results obtained 
with healthy donors (N; mean values ± SEM) and 3 patients (pt) after HSCT are shown. 
 
 
 
These results indicate that the CD16-/dim NK cells, which are present in increased 
proportions in the early posttransplantation period, have the ability to readily respond to 
the cytokine stimulus and produce IFN-γ comparable to NK cells from healthy donors. 
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VI. Discussion 
 
 
1. Expression and Role of NK Activating Ligands in 
 Normal PB Cells 
 
Recently, MIC and ULBP molecules have been identified as activating ligands for 
NKG2D in humans13,104. MIC surface expression was described in epithelial tumors. The 
presence of surface MIC resulted in the killing of tumor cells by NKG2D expressing NK 
cells and T cells. Expression of ULBP molecules by several tested tumor cell lines lead to 
NK mediated cell lysis, too. So far, only little information has been published concerning 
NKG2D ligand expression in normal cells. Two groups found ULBP mRNAs in MNCs 
of healthy PB and BM13,109 but ULBP and MIC protein expression was published to be 
absent in MNCs13,104. In contrast, in our study B cells, monocytes, granulocytes and 
platelets were identified as ULBP expressing cells. ULBP1 was always expressed at 
highest levels in B cells and monocytes. In platelets ULBP2 was the main ULBP ligand 
expressed. The ligands were absent on T cells, NK cells and erythrocytes. We also found 
MIC expression on monocytes and B cells. The controversy of our results with previous 
studies can be explained by our gating on distinct cell lineages. When analyzing ligand 
expression on total MNCs, as was done previously, ligand negative T cells, which are the 
main MNC population, hide potential ligand expression on B cells and monocytes. 
Using real-time PCR we detected ULBP1, ULBP2 and ULBP3 transcripts in B cells, 
monocytes and T cells, confirming expression of these ligands by subpopulations in 
normal PB. However, transcript levels were low and did not correlate with the cell 
surface density of individual proteins. A discordance in expression of ULBPs at mRNA 
and protein levels was also seen with tumor cell lines13, suggesting that ULBP expression 
is regulated at a level other than transcription. 
Importantly, no cellular ligands have been discovered for the NCRs, yet. In order to 
identify cells expressing potential NCR ligands we used dimers of soluble recombinant 
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NCRs. Binding of these dimers demonstrated that, similar to NKG2D ligands, B cells and 
monocytes express potential NCR ligands. 
 
We found that expression of NKG2D ligands and putative NCR ligands on monocytes 
and granulocytes varied between different healthy individuals. To explain this 
phenomenon donors with ligand negative monocytes were tested for hCMV infection, 
since ULBP1, ULBP2 and MICB are downregulated in hCMV infected cells100-102. 
However, there was no correlation between hCMV infection and ligand expression in 
monocytes (data not shown), indicating that differences in cell surface ligand levels are 
not CMV-related.  
As we hypothesized that activation of myeloid cells may be a reason for ligand 
expression purified ligand negative monocytes were analyzed in vitro for conditions 
which may lead to ligand upregulation. So far, only very little was known about 
regulation of NKG2D ligands. It was shown that expression of MICA/B increases in 
response to various forms of cellular stress, including diseases such as tumor 
transformation and arthritis86,98. Heat-shock transcription elements present in the 
promotor regions of their genes are thought to be responsible for induction of MIC 
molecules, but have not been implicated in regulating the expression of ULBPs. Except 
for upregulation of ULBP3 in CMV-infected cells100, signals regulating expression of 
ULBP proteins and the as-yet unknown NCR ligands have never been described. 
We found that ULBP1 and putative ligands for NKp30, p44 and p46 were selectively 
upregulated in response to myeloid growth factors FL, SCF and GM-CSF. This 
upregulation was further enhanced by addition of IFN-γ. ULBP2 and ULBP3 were not 
affected by neither growth factors nor IFN-γ. Other inflammatory cytokines, such as IFN-
α, IL-1β and TNF-α, and LPS which are known to stimulate monocytes were unable to 
elevate surface levels of ULBPs. These results showed that ULBP1, ULBP2 and ULBP3 
are regulated by different pathways. The fact that ULBP molecules are expressed at 
different levels and that they don’t share the same regulation mechanism implies different 
physiological roles for ULBPs. Different ligand functions may also explain the presence 
of so many cellular ligands, which bind with distinct affinities13 to the same receptor.  
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The presence of triggering ligands on monocytes did confer susceptibility to attack by 
NK cells when HLA class I molecules specific for inhibitory KIR receptors were masked 
by mAbs. Only 11% of ligand positive monocytes used as targets for autologous NK cells 
were killed in vitro at an effector to target ratio of 10:1. Blocking of MHC class I ligands 
by mAbs increased the killing to 26%. Remarkably, ligand negative CD34+ progenitors 
were fully resistant to cytolysis by autologous NK cells and remained protected also after 
blocking inhibitory MHC class I ligands. Thus, missing inhibitory signaling is not 
sufficient for NK cell recognition but engagement of activatory NK cell receptors are also 
needed. However, in monocytes level of triggering NKG2D and NCR ligands is 
apparantly too low to overcome protective inhibitory signaling. 
The physiological relevance of ligand expression on B cells and myeloid cells is not 
clear. However, interaction between those cells and NKG2D expressing NK cells has 
already been demonstrated in previous studies. NK cells can interact with B cells 
resulting in maturation and immunoglobulin production by B cells192 and conversely, 
secretion of cytokines by activated NK cells193. Interaction of monocytes with NK cells 
causes proliferation and production of cell type-specific cytokines175,176. Adhesion 
molecules, such as CD11a and CD54, as well as CD40 and CD40 ligand were implicated 
in these interactions and it remains to be seen whether ULBPs and NCR ligands 
expressed by normal blood cells function as co-stimulatory molecules for cells bearing 
cognate activating receptors. 
 
When we analyzed in vitro generated DCs we found no surface expression of ULPB1, 
ULBP3 and MICA/B. However, immature and mature DCs were shown to activate NK 
cells dependent on NKp30 and to a lesser extent on NKp46182, indicating that human DCs 
are expressing ligands for activating NK cell receptors. The detection of such ligands on 
DCs needs further investigations. 
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2. Expression and Role of NK Activating Ligands in 
 AML 
 
Acute leukemia is characterized by a rapid disease progression. The high incidence of 
relapses following treatment with high-dose chemotherapy or transplantation of 
allogeneic hematopoietic stem cells189,190 suggests that leukemic blasts can escape 
recognition by the immune system. To explain the poor immunogenicity of malignant 
blood cells, we examined the expression of ligands for NK cell-activating receptors in 
human AML. We found that leukemic transformation is frequently associated with an 
absence or low cell surface density of ligands for NKG2D and NCRs, which may render 
the blasts insensitive to recognition by NK cells. 
Staining of cells with mAbs specific for ULBP1, ULBP2, ULBP3 and MICA/B, and 
binding of soluble NCRs which reflects the distribution of putative NKp30, NKp44 and 
NKp46 ligands, demonstrated that ligand levels on leukemic blasts are very low in the 
majority of patients with AML. ULBPs were not detectable or low (MFI ratios of 1.0-2.0) 
in 23 out of 30 patients (77%), as were NCR ligands in 10 out of 12 patients (83%) and 
MICs in 6 out of 9 patients (67%). This confirms and extends a recent report of the 
ULBP-negative/low phenotype of primary leukemic blasts in 12/15 AML patients194. A 
low density of ligands triggering the NKG2D and NCR receptors in AML implies that 
interactions between activating receptors and their ligands may be insufficient to elicit 
strong cytolytic responses against the leukemic blasts. 
Unlike leukemic cells, the residual normal monocytes, granulocytes and B cells in 
patients with AML expressed ULBPs and showed binding of soluble NCRs in 
comparable levels as in healthy donors. 
Importantly, expression of ULBPs and NCR-specific ligands increases during 
hematopoietic cell differentiation. In healthy human BM, early CD34+ progenitors are 
negative for ULBPs, MICA/B and NCR-specific ligands, whereas CD34- committed 
myeloid progenitors carrying CD33 and CD14 markers display the ligands on the cell 
surface. Consistent with this, growth factor-induced myeloid differentiation of CD34+ 
cells in vitro is accompanied by the acquisition of the activating ligands. In AML, ligand 
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surface density appeared to correlate with the hematopoietic differentiation stage at 
which leukemic transformation took place, since ligand-positive blasts prevailed in AML 
patients with monocytic M5 and megakaryocytic M7 blasts which are more mature 
progenitors. ULBP-negative or ULBP-low blasts were found in AML of subtypes M1-
M4 affecting early stages of hematopoiesis, confirming previous results in 15 M1-M4 
AMLs194. In vitro culture of leukemic blasts from 2 out of 5 AML patients with myeloid 
growth factors was associated with upregulation of triggering ligands, arguing further that 
the ligand-low phenotype in AML is related to early maturation arrest during malignant 
transformation. Ligand expression could further be increased when cultures were 
supplemented with IFN-γ. Importantly, upregulation of the ligands on leukemic blasts 
correlated with elevated cytolysis of blasts by allogeneic NK cells from healthy donors. 
This lysis was in part dependent on the activation of NKG2D, since blocking of its 
interaction with cognate ligands by mAbs resulted in a decreased killing of up to 43%. 
These findings show the relevance of ligand expression on tumor cells for NK cell 
recognition. 
Upregulation of ligands in response to IFN-γ is accompanied by elevated levels of MHC 
class I ligands. Thus, when we used allogeneic NK cells with at least one match in HLA 
alleles, recognition of blasts by NK cells was hampered through inhibitory KIRs and 
killing was only induced after blocking inhibitory signals.  
Ruggeri et al recently showed that in haplotype mismatched HSCT allogeneic NK cells 
exert an antileukemic effect due to KIR mismatches between effectors and targets127,128. 
Growth factor and IFN-γ induced expression of triggering ligands on blast of patients 
may thus improve cytolysis of tumor cells by donor derived NK cells independently of 
HLA class I upregulation on blasts. Furthermore, identification of compounds that 
selectively elevate ligand levels on tumor cells without affecting MHC class I levels 
might be of interest for clinical use and warrants further investigation. Accordingly, 
clinical use of G-CSF concurrently with chemotherapy has improved long-term survival 
in AML195 and one might speculate that the observed reduced incidence of relapses is 
related to the enhanced susceptibility of cytokine-treated blasts to killing by the immune 
effector cells.  
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Our results so far indicated that low expression of activating ligands may be responsible 
for the poor immunogenicity of leukemic blasts. Other reasons for insufficient tumor 
recognition by NK cells might be the presence of MHC class I molecules on blasts 
engaging inhibitory receptors on NK cells or diminished NK cell function in patients with 
AML. Indeed, we found that MHC class I ligands were present on leukemic blasts in 
comparable levels as in residual MNCs of AML patients. However, MHC class I 
expression was significantly reduced 2-fold on patients blasts compared with MNCs of 
healthy donors. These results indicate that due to reduced levels of inhibiting ligands, it 
might be possible to overcome the negative signal by inducing expression of ligands for 
activating NK cell receptors. 
Analysis of NK cells from AML patients revealed a significant reduction of relative NK 
cell numbers in MNCs of AML patients, with 2.8 ± 0.6 % NK cells per MNCs, compared 
to 7.0 ± 1.5 % NK cells per MNCs in healthy donors. In addition, we also found a 
significant decrease in T cells and monocytes. These findings indicate an impaired 
immunity due to reduced numbers of effector cells responsible for tumor recognition. 
NK cells from AML patients expressed the activating receptors NKG2D and NKp46 at 
normal high levels suggesting that recognition of ligand expressing target cells is not 
impaired. Our results differ from a previous report describing a NCRdim phenotype of NK 
cells in AML79. This discrepancy is apparently due to the fact that we analyzed fresh NK 
cells in PB, whereas Costello et al cultured NK cells prior to detection of receptors. Thus, 
it is possible that NK cells from AML patients downmodulate surface NCRs after in vitro 
proliferation. 
In 5 among 22 AML patients only 0.1 – 9.7 % of NK cells expressed the activating Fcγ 
receptor CD16, which is normally expressed on 90% of NK cells16. NK cells in these 
patients therefore might display a diminished cytolytic activity and recognition of 
opsonized target cells by NK cells is possibly reduced. 
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3. Characterization of NK Cell Compartment after 
 HSCT 
 
HSCT is a common treatment in AML and recent studies have shown an important GvL 
effect of donor derived NK cells in haplotype mismatched transplantations127,128. We 
investigated the recovery of NK cells after HSCT and their phenotypic and functional 
properties.  
The reconstitution of NK cells after grafting was very rapid. As soon as 7 days after 
HSCT NK cells comprised 1.98 ± 1.6 % of PB total nucleated cells and reached normal 
levels of 3.09 ± 0.73 % at 3 months. However, absolute NK numbers are significantly 
decreased in patients undergoing HSCT and only return to normal levels (12.72 ± 2.15 x 
10-4 cells per mL) at 6 months. Analysis of NK cells in BM of patients was first done 14 
days after HSCT and revealed that NK cell levels of 0.97 ± 0.30 % were comparable to 
healthy donors, whose BM MNCs comprised 0.76 ± 0.24 % NK cells. According to a 
recent chimerism study, the major proportion of NK cells is donor derived127 and, at this 
early time point, may represent a mixture of cells transferred with the graft and those 
developing from the newly engrafted hematopoietic progenitors. 
Phenotypic analysis of NK cells from transplanted patients revealed that the NKp46 
receptor is expressed normally. However, the activation markers CD69 and HLA-DR 
were significantly increased on NK cells from patients after HSCT. In contrast, CD161 
which was shown to inhibit target lysis induced by engagement of NKp46 or CD16196, 
was reduced. These findings indicate that developing NK cells in patients after 
transplantation are highly active. 
Further phenotypic characterization of developing NK cells demonstrated a 
disproportional 5-fold increase in poorly cytotoxic CD56brightCD16dim/- NK cells over 
highly cytotoxic CD56dimCD16bright NK cell subset. This skewing of NK cell subsets 
persisted for 6 months and was in line with previous results197. Previously, it has been 
shown by our group that FL serum levels are highly elevated in patients treated by 
chemotherapy preceding HSCT198,199. Since NK cells generated from CD34+ progenitors 
in vitro in response to FL are predominantly of the CD56brightCD16dim/- type11, high serum 
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FL might contribute to this skewed proportion of NK cell subsets in patients undergoing 
transplantation. 
Our results suggest that CD56bright NK cells develop more rapidly in vivo and that 
CD56dim NK cells either require more prolonged exposure to maturation factors or arise 
from CD56bright cells. Actually, it is still discussed whether CD56bright NK cells represent 
an immature NK subset. The fact that CD56bright NK cells highly proliferate and acquire 
cytotoxic potential in response to IL-2 and IL-15, whereas CD56dim NK cells are already 
cytotoxic and have a low proliferative capacity in vitro, supports the hypothesis that 
CD56dim NK cells derive from the CD56bright subset. The recently discovered IL-21 has 
been shown to induce generation of NK cells with a CD56dimCD16+ phenotype from 
progenitors in vitro200. Thus, it remains unknown whether CD56dim NK cells develop 
from a unique precursor or whether additional soluble, such as IL-21, or cell-contact 
signals are required for the generation of characteristic CD56dimCD16bright NK cells. 
 
To test the capacity of developing NK cells from transplanted patients to produce IFN-γ, 
CD56brightCD16dim/- NK cells were purified and expanded in vitro. IFN-γ production was 
measured in response to IL-12 and IL-18 and was normal compared with 
CD56brightCD16dim/- NK cells from healthy donors. In contrast, lysis of MHC class I-
deficient K562 cells by patient derived NK cells was reduced 3- to 4-fold, compared with 
NK cells from healthy donors201. It was suggested that this significant difference might be 
related to the reduced content of highly cytotoxic CD16bright subset within the NK-cell 
population. 
Because recovery of T cells after myeloid ablation preceding HSCT is delayed and it may 
take years before T-cell immunity is restored202,203, the rapid expansion of donor-derived 
NK cells has particular implications for the functional immune recovery in the early 
period after HSCT. Interactions between NK cells and also early recovering DCs201 
underlie the main immunologic responses important for induction of tolerance to prevent 
GvHD and for an antitumor effect to prevent relapse. 
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So far several escape mechanisms from NK cell recognition have been described; 
epithelial tumors have been demonstrated to secrete MIC ligands which bind to NKG2D 
receptors on NK cells and T cells thereby leading to their internalization resulting in 
reduced cytolytic activity of the effector cells. Furthermore, viral protein UL16 from 
hCMV is binding to ULBP1, ULBP2 and MICB and retaining the ligands intracellularly. 
In AML, we showed that triggering receptors on NK cells are not affected. However, our 
results indicate that the absence of surface ligands for activating NK cell receptors on 
leukemic blasts due to their insufficient maturation, provides tumortransformed cells with 
the advantage to evade NK cell recognition.  
Together with our results demonstrating rapid recovering NK cells after HSCT, 
expressing normal levels of activating receptors, in vivo application of compounds, 
increasing surface expression of NKG2D and NCR ligands, together with the selection of 
donors for stem cells and NK cells with appropriate HLA class I mismatches suitable for 
tumor clearance, may be used as an immunotherapeutic strategy to reduce leukemic 
relapses. 
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